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Thi issue includes a broad pectrum of articles appealin g to
readers of all backgrounds and interests. Fro m the newe t surgical
advances, diagnostic modalities and techniques, to bread-and-butter
management guidelines, we hope that thi s issue will piqu e yo ur interest
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Your feedback, co mments, idea , and questions are welco med
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represents the opinions o f the
authors and not necessaril y th ose of
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Clinical Procedures
Current Techniques in Carotid Artery Stenting: A Synopsis
Paul Lau, Meds 2011
Reviewed by Dr. Stephen P. Lownie

Introduction
Cardi ova cul ar di sea e and tro ke are the leadin g
cau e of death in Canada. Approx imately
15,000 Canadians will di e o f troke every year
and 300,000 peopl e w ill be li ving with its
1
effec ts. In the United States of Ame1ica, 30 % of
all stro ke related death were associated with
2
carotid artery le ions, a tati tic likely imilar in
Canada.
The commone t carotid artery disease is
teno i , where there i narrow ing of the carotid
artery lumen. Becau e the carotid arteries are the
principal blood uppl y to the brain , decrease o f
fl ow as a result of stenos is can cause transient
i c hemic attacks or in the ca e of complete
occlu sion, cerebro va c ular accidents? The
majority of carotid arte ry stenos is case are a
re ult of atherosclerotic pl aque acc umul ati on in
the wall of the arteri e . Therefore, a second ary
ri k factor in carotid atherosc lerotic steno i
is
the di slodging
of e mboli
to
the
3
cerebrovasculature.
Indeed, the rupture or
di lodgement of plaques cau ing down tream
e mboli acco unt for the majority o f carotid artery
stroke .
Pati ent with carotid stenos is can be
asymptomatic or present with a tran ient
i chemi c attack or stro ke. 2 ·3 Di ag nos is is made
u ing several technique. . Upon ph y ical
examin ati on, carotid au c ultati on may reveal
a
carotid
bruit.
o mputed
tomograph y
angiography, magneti c reso nance angiograph y or
carotid dupl ex ultra o nograph y are vari ous
im ag in g modaliti es u ed to di ag nose suspected
4
carotid steno is. Furtherm ore, these im ages
permit the surgeon or interventi onali st to
calcul ate the degree of teno is, an important
con iderati on in tenn s of dec idin g between
vari ou treatments.
Several treatments have been approved
for improving outco mes o f pati ents with carotid
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artery stenosis. Currentl y, endarterectomy or
urgical removal of the narrowed carotid
egment is the accepted and most widely used
treatment for carotid teno i 5 ; however, carotid
artery tenting ha ri sen a a non-invasive
altern ative for orne patient with the aim of
4
restoring the carotid lumen. Thi s article will
ex plore the procedural as pect of carotid stenting
and pre ent the indi cati on and contraindication
fo r thi interventi on.

Carotid Stenting
Procedure
The non-in va ive nature of carotid tenting
permits the pati ent to be awake during the
procedure. Thi allow the physician to monitor
the patient's neuro logical tatus; 2 an important
con ideration due to the po ibility of embolism
to the cerebral ve e l . The procedure i
performed in an angi graph y suite under the
guidance o f flu oro copy. Co ntras t agent are
constantl y admini tered to direct catheters and
co nfirm po iti onin g of balloon and te nt .
A needle is in serted into the common
fe moral artery under local anaesthesia. A radioopaqu e guidewire i then threaded throu gh the
needl e and advanced into the abdominal aorta.6
The needl e is ub. equ ntl y re moved and a heath
i pl aced over the guidewire and advanced to the
ao rta. At thi po int, the guidewire is al o
re mo ved and the sheath act a a catheter by
whi ch other catheter and wire can be pl aced
and guided towards the tenos is?·6
Using catheter , a preliminary carotid
angiogram i conducted to demonstrate the
degree of teno is (ex pres ed a a percentage)
and a e s for artery ize down stream of the
le ion. Thi s allow the ph y ician to choose the
appropriate Embolic Protection Device (EPD)
and tent based on degree of steno is and ize f
2
the artery re pective ly. A ce re bral angiogram i

also perfonned to rule out any contraindication
to carotid stenting. Appropriately, heparin is
administered to prevent clotting and its effect is
measured using the Activated Clotting Time
(ACT). The ACT in thi s procedure should
exceed 250 seconds.
An EPD i a specially des igned umbrella
haped device that is used to capture debri s and
emboli as a result of either Percutaneous
Transluminal Angioplasty (PTA) or the release
of a stent compressing the artherosclerotic
7
plaque. Before the stent is placed, an EPD is
deployed upstream with re pect to the site of
stenosis. The use of an EPD has shown to reduce
the ri k of ischemic attack 30 days post
procedure to 2.2% from 5.3%? This has
prompted the routine use of an EPD by many
interventionalists. If the degree of con triction is
too evere to safely allow an EPD through , PTA
with a small balloon may be appropriate to allow
for safe pa sage of the EPD.
At thi s point, a sheath covered stent is
introduced and directed towards the site of the
lesion . The sheath is peeled and removed and the
stent is positioned in the stenotic portion of the
artery. 6 The stent is self expandable and will
effectively reduce the degree of stenosis.
Following stent deployment, an angiogram is
obtained to confirm the increase in diameter of
the artery.
In severe cases of stenosis, the stent itself
may only reduce the occlusion mildly? To
combat the high degree of post procedure
stenosis, a balloon catheter may be placed within
the boundaries of the stent and expanded to
allow for greater augmentation of the vessel
diameter. Similarly, it i essential to confirm
with an angiogram the degree of post procedure
stenosis. Importantly, the placement of the
balloon should not extend further then the
margins of the stent. Damage resulting from
inflation of exaggerated balloons may cau e
damage to vessel walls and increase the ri sk of
restenosis. Angiogram confirmation of arterial
lumen expansion is followed by catheter
26
dependent removal of the EPD. ·
Results from a recent study proposed that
because pre- and post-stent deployment balloon
angioplasty may be the major cause of dislodged
emboli in carotid stenting procedures, that

removal of the e step in carotid tenting wou ld
elimin ate the need for EPDs.8 This study
demonstrated that the u e of elf expanding
stents alone provided moderate allev iation of
teno i with increasi ng lumen diameter for up to
one year. In co njuncti on, none of the patient in
the study had a troke as a direct result of the
proced ure. The implicati ons of this tud y are
twofold . Firstly, PTA may be the majo r cau e of
emboli related co mpli cations in carotid tenting
and secondly, if PTA is not u ed within the
procedure, EPDs may not be necessary.
Effectively, the e modifications to the carotid
stenting
techniqu e
may
provide
future
intervention alists with a afer, qui cker, more cost
efficient procedure.

Pre-procedure Considerations
Carotid
tenting is onl y advised over
endarterectomy in a subset of patients. Currently,
within the context of a randomized control trial,
any symptomatic patient (tran sient ischemic
attacks or stroke) with greater th an 60% carotid
artery stenosis or asymptomatic patients with
greater than 80% stenosis are eligible for carotid
stenting? Additionally, individual deemed to be
at a high ri sk for surgery or who have had a
previous endarterectomy with recurrent stenosis
are also eligible for stenting. Some exclusion
criteria include individuals with torturou s aortic
arches , unfavo urable anatomy, inaccess ible
lesions and patients with contraindications to
anticoagulation therapy.
If approved for carotid artery stenting,
patients should undergo a full neurological
examination as well as a neurological angiogram
24 hours pre-procedure. Antiplatelet therapy
should be given four day
prior to the
intervention ; however, patients who are over 80
years of age may require lon ger treatment
periods. Acetylsalicylic acid and clopidogrel are
administered once daily to the patient. 6
Post-Procedure Considerations
Following the intervention , the patient' blood
pressure should be kept under 160mm Hg and
antiplatelet therapy continued for 6 weeks.
Following these 6 weeks, the patient should be
advised to continue acetyl salicylic ac id
treatment for the duration of their life.
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Conclusion
Although endarterecto my ha proven hi ghly
ucce sful in the treatment of carotid artery
steno i , carotid artery tenting has emerged a
an altern ative. On the pati ent level, carotid
tenting may prove to be a safer procedure
for specific indi vidu al . However, stenting
of the carotid artery is a technically
challenging interventi on with numerous potenti al
complicati on that make it un favo urable a
a standard therapy when compared to
4
endarterectomy. Recent tudi e have hown the
non-in fe rior nature of carotid artery tentin g
compared to carotid endan erecto my in a tri al
u ing asympto mati c pati ent w ith greater th an
80% teno is or ymptomati c pati ents with
greater than 50% teno i .9 However, increa ed
ri k of post procedu re co mplicati ons of tenting
have been docum ented in a tri al co nsi ting of
onl y y m ~ to m a ti c patient with greater th an 60
steno i . 1 These tudies demon trate th at in
pecific pati ent populati ons stenting may be
preferred but upport fo r carotid artery stentin g
a a routine treatment for carotid stenos is is
lacking.
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Diagnostic Review

Innovations in Cardiac Computed Tomography: Cone Beam CTN olume CT and
Dual Source CT
Jaron Chong, Medicine 2010 and Jason Essue, Medicine 2011
Re viewed by Dr. Ali Islam
Two recent inno vati o ns in cardi ac Co mputed T omograph y (CT) o f Co ne Beam CT or Vo lume CT ( VCT ) and more
recentl y, Dual-So urce CT (DSCT) o ffe r phys ic ians c linica ll y viabl e a ltern ati ve to in vas ive coronary angiography for
the imag ing o f coronary artery ste noses. Performing the procedure termed CT angiography or Multi -Detector CT
angiograph y, both techno log ies provide the neces ary pati al and te mpo ral re o luti o n, in additi on to a vari ety of o ther
ad vantage to image the cardi ac patient. Both report improvements over co nve nti o na l CT with reduced acqui sitio n time,
greater image quality, and with DSCT an ability to perform cardiac imag ing on tac hycardic patient a well as reduce
radi ati o n dose, all witho ut co mpromi sin g image quality. Whil e o nl y being two exa mple of new tec hno logie in cardi ac
imaging, VCT and DSCT represent the c urre nt and next steps, in wh at pro mi ses to be many excitin g developme nts to
co me .

Introduction
The field of Computed Tomography (CT) has
realized many significant developments over the
past four decades that have dramatically
improved the clinical applicability of thi s
1
technology. CT became widely available in the
1970s with the introduction of ingle-detector
CT canners that captured one slice per rotation .
In 1992, the first Multi-Detector CT (MDCT)
scanner was produced (CT-Twin, Elscint)
capturing two slices per rotation. 2 Since then , the
field has advanced to the point where modem
MDCT scanners are routinely able to capture up
to 64 slices per rotation. 3
The past decade has seen multiple
generations of CT scanners emerge, and when
64-slice scanners first arrived, the ensitivity and
specificity of detecting coronary artery stenosis
via CT angiography began to approach that of
4
invasive angiography. In year pa t, what some
in the press have dubbed the 'slice wars'
between the four major vendors of GE, Siemens,
Toshiba, and Phillip in the push for greater
spatial and temporal resolution has evolved into
a more complex marketplace with different
5
vendors pursuing different strategies. Toshiba
has decided to pursue greater slice count to an
industry record of 320 slices and coverage area
up to 12cm. 6•7 Phillips has taken efforts to
increase the gantry rotation speed (i.e. the speed
at which the X-ray sen ors rotate around the
patient) which in conjunction with reconstruction
algorithms provides a temporal resolution of

270ms. 8 However, for the purposes of this
article, we will be reviewing in greater detail
GE 's Volume CT (VCT) and Siemens' DualSource CT (DSCT) systems.

-~~

Figure 1: 30 Vo lume Re ndering of the Heart. 3

Cardiac CT Imaging
With re pect to cardiac imaging, many efforts
utilizing CT have focu sed on the imaging of
coronary artery steno es, a technique tem1ed CT
angiography or MDCT angiography (Figure 1).
In comparison with the gold tandard of invasive
conventional coronary angiography, noninvasive CT has the advantage of avoiding ri ks
of arterial vascular complications such as arterial
punctures, vessel damage, and dislodged aortic
plaques causmg myocardial infarct or stroke.
UWOMJ 77(2) 2008 7

Estimate place the total risk of an adverse event
between 1.7-2.0% for all causes. 9- 11 In contrast,
the major ri sks of CT angiography are a reaction
to intravenous contrast and the radiation dose
potentially cau ing cancer, both of which are
equally
present
in
traditional
inva ive
angiography. The risk of a severe or fatal
anaphylactic reaction to contrast is estimated at
0.04% and the lifetime ri sk of dying from cancer
due a CT angiography can is estimated to be
le s than 0.1 %.9 With regards to the radiation
dose, significant advance have been made to
decrease
the
radiati on
abso rbed
while
maintaining image quality and is the focus of
much active re earch.
Cardiac im aging poses th e very unique
challenge of im aging a moving target, requiring
any clinically effective scanner to compl ete an
image acquisition during an akinetic end- y tolic
or dia tolic period. 12· 13 A a natural co nsequence
of thi , the faster a scanner can complete a
rotation to avoid parts of the cardiac cycle with
motion , the clearer the image will be, generall y
speaking. Thi s quick scanning speed also prove
advantageous during tachycardia without the
need to use drugs like beta-blockers for heart rate
control.

Cone Beam CT/Volume CT
Conventional MDCT canners collect
projection from a fan beam of x-ray . 14 • In
compari on, Cone Beam CT or Volume CT
(VCT), expand the x- ray beam from a fan to a
pyramid or co ne (Fi gure 2). 3 ' 14 A computer
algorithm then proces es the 20 cone-beam
projections into a 3D image of a patients'
X ·MAY COH£ UEAM

lfoiACH! IHTEHSI FI( R

O IIJ Cl ROTATC5 IN
K · RAY BE t.M TO Tt. K E
IMAGES DATA FAOM

All .I<_HG LES
)( , ItA_ Y S OU RCC

IIOLUIU CT
RECOHSTMUC.TION

Figure 2: Cone-Bea m CT concepl.
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14

anatomy. With the advent of scanners a?le to
capture up to 64-slices per rotation, this has
created the platform necessary for Volume CT to
emerge. 3
One such scan ner is the LightSpeed VCT
model introduced by General Electric (GE) in
2004. GE 's LightSpeed VCT canner features a
64-slice detector and rotation speed of 370
milli second
with slice widths of 0.625millimeters, enabling the system to generate 64
sub-millimeter images totaling 40 millimeters of
. coverage wtt
. h a mg
. 1e rotatiOn.
. 14, ts GE
anato mic
attributes
orne of the image acq uisition
improvement to the development of a new
detector technology named V-Res, which is able
to acquire 64 channels of data while spinning at
le th an 0.4 second per rotation .3
The combination of hi gh volume and
high re olution demon trated by the LightSpeed
VCT scanner translates into three major tangible
clinical benefit :
Dramatically reduced acquisition time: Scanning
time i half that needed for conventional MDCT
scanners. Static organ can be imaged in one
econd , the lung in two econds, the heart and
coronary arterie in fewer than five econds, and
a whole body scan in les than 10 seconds. 3• 15
The quicker imaging process
more
comfortable for patients because it requires
horter breath-holds, can be especially u eful for
trauma patients when time i of the es ence, and
may help to allevi ate lengthy queue for
diagno tic imaging given that a hi gher volume of
patient can be imaged on a given day. 3
Improved image quality: The characteri tic thin
slicing capacity of the Volume CT allows for the
generation of hi gh resoluti on image , which
translates to better diagnostic accuracy. 16 • 17 In
addition , multi-planar reformatting of images in
any plane, including curved planes, i al o
po ible. This improves the depiction of
pathologic features paLticularly in cardiac
imaging because s uch tructure do not lie in the
tandard planes (x , y, z), which also improve
diagnostic accuracy. 18•19
New diagnostic possibilities: Volume CT offers
the po sibility to acquire a complete angiooram
within five heartbeat
(at 60 beat fmin
approx im ately 5 seconds) making the procedur~
less u ceptible to irregular heartbeats, helping

phy ician rule out, or in, the three main causes
of life-threatening ER chest pain (i.e. aortic
dissection , pulmonary embolism, and coronary
artery di ease) in one can, and en ure a more
thorough troke work-up because the entire
Circle of Willis can be dynamically acquired
with high reso lution. 3
More recently in 2007, GE introduced the
LightSpeed VCT XT scanner (an improved
ver ion of their LightSpeed VCT canner) that
operates on a new scanning platform called
'SnapShot Pulse', which claims to reduce
radiation dosage by a much a 70-83 % when
compared to conventional helical techniques
without compromi ing image quality by pul ing
the x-ray beam during akinetic portions of the
cardiac cycle as orposed to continuously
engaging the beam ?0-2

Dual-Source CT (DSCT)
Dual-Source CT, a more recent development,
innovates upon modem CT system by utilizing
multiple X-ray source and detectors to reduce
the length of time required to perform one
canner pas . A of thi s writing, the only
commercially DSCT sy tem available, known a
the SOMATOM Definition, is manufactured by
Siemens Medical Solution . Utilizing two X-ray
tube sources and two corresponding detectors
offset by 90·, the SOMATOM system yields
significant gains in temporal reso lution making it
ideal for cardiac application (Figure 3)?3
In a typical si ngle- ource CT canner, the
length of time required to perform a scan i

limited by what is known a the 'gantry rotation
time' which can range from 0.33s to 1.0 . Thi i
the amount of time it phy ically takes to rotate
the fan-shaped X -ray source and detector 180.
through the field of view gathering the necessary
images to re-con truct a slice or array of sli ces.
By utili zing the second-so urce X-ray tube and
detector array, the time taken i halved to 165m
5
while maintaining equivalent spatial resolution ?
Steady Imaging Up To 100 BPM: The ability to
image at this enhanced speed has numerou s
implications for the cardiac imaging challenges
mentioned earlier. DSCT allows for teady
imaging of the heart irre pective of heart rate up
to 100 beats/min whereas a ingle-source CT can
only guarantee temporal re olution at 66
beats/min or lower (Figure 4)? 6 Thu , with
single-source CT, stringent protocols are
required duting Coronary CT Angiography
(CCTA) to lower a patient' s heart rate to less
than 65 beats/min using beta-blocker . Such
compensations are optional with DSCT. 27 •28
Increased Pitch/Reduced Radiation Dose at
High Heart Rates: Another advantage of DSCT
is the ability to increase pitch (i.e. the speed at
which the patient is advanced through the
scanner) for any given heart rate thereby
reducing the duration of time the patient is
exposed to radiation, and hence, overall radiation
dose. A study conducted by McCollough et al.
examined the dose performance of the
SOMATOM in comparison to traditional multi29
detector CT. The study noticed a dec rea e m
radiation exposure when radiation do e
22(
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Heart rate in bpm
Figure 3: Configuration of Dual-Source CT scanner with
two X-ray tube sources and two corresponding detectors
. 24
offset by 90 .

Figure 4: Comparison of ingle-source versu dual- ource
CT. Note the preservation of temporal resolution despite
increasi ng heart rate. 24
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o ptimization methods were used for patients with
high heart rates close to a facto r of 2 (At >90
beats/min: 26.6mGy DSCT vs. 43.7mGy
MDCT). However, this advantage is lost and
almost co mpletely reversed when imagin g at
very low heart rates (At <55 beats/min : 6 1.2mGy
DSCT v . 28. 7mGy MDCT).29 ·30
Consistent Image Quality: All of these
advantage wo uld no t be particul arly useful if
di agnostic quali ty were compro mi sed bu t DSCT
maintain high standards in spite of hi gh heart
rates. M att et al. managed to de monstrate no
significant correlation between between mean
heart rate and image qu ali ty in a populatio n of 80
patient that underwent DSCT, with heart rates
ranging from 35 to 99 beat /mi n.31 In contras t,
o ther studie with 64- li ce MDCT have hown a
decrea e in image quality with inc reas ing heart
rate.32,33

Conclusion
Both Cone-Beam CT I Volume CT and Du alSource CT represent two example of recent
developments in cardiac im aging. While vendo r
have an interest to push the edge of techno logy
to even greater height , re earchers, clinic ians,
and policy makers have an equ ally impo rtant
re ponsibili ty to evalu ate the e new techno logies
w ith an eye toward efficacy, clinical benefi t, and
pro per indications for u age.
N umerous
developments in CT scanners are cutTentl y
18
undergo ing clinical evalu ati o n, and research is
being conducted into further strategies for bo th
reducin g radiatio n do age whil e im provin g
im age qu ali ty. Several ve ndo rs are alread y
looki ng at d ual-energy CT that has the potenti al
to improve characteri zation o f varyin g tiss ue
4 5
densiti es and minimi ze metal im age artifac ts? .3
It may be many years befo re we see w ide-s pread
adopti on o f the e techno logies here in Canada,
but there can be no do ubt a to the impo rtant
im plicati o ns of wo rk like thi . T wo sources or
o ne, 320-or 64-s lices, cardiac imaging is onl y
just getting started .
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Ethics
The Aprotinin Story: Lessons in Drug Regulation and Safety
Adam Katchky, Medicine 2010 and Christina Morgan, Medicine 2011
Reviewed by Drs. Lois Champion and Mark Speechley
Issues o f drug regul ati on and safety are a fami li ar co ncern within the pharmaceutical industry a nd ofte n do not emerge
until several year after a drug ha been on the market. The antifibrino lyti c drug aprotinin (Trasylo l) was developed
by Bayer Pharmaceutica l and approved to prevent excessive bleeding in patients undergoing coro nary artery bypass
graftin g surgery. After evera l year o f widespread use o f the drug in cardiac proced ures, two ob ervational studies
demo n trated a ri k of aprotinin for erious co mpli cati o ns such a renal failure and myocardial infarction . These
observations led to a prol onged rev iew of the drug 's safety label by the Food and Drug Adrniru trati on and to the
revelati on that Bayer had w ithhe ld the result o f a private ly co mmi s io ned observational study which demon strated
these reported co mplicati ons. Thi s essay hi ghli ghts the ethica l iss ues rai sed by the aprotinin aga a nd di cu es the
importance of transpare ncy, honesty , and clini ca l equipo ise in drug regul ati on and safety.

Timeline
On December 30, 1993, the Food and Drug
Admini stration (FDA ) announced it approval of
the antifibrino lytic agent, aprotinin , developed
by Bayer Pharm aceuticals and marketed under
the trade name Trasylol for use in cardiac
1
urgery. Antifibrinolytics have long been a
main stay of treatment to prevent excessive
bleeding, a frequent cause of morbidity and
mortality in patients undergoing on-pump
coronary artery bypass grafting (CABG ) and
other
cardiac
procedures.
Traditional
antifibrino lytic agents, including an1inocaproic
ac id (ACA) and tranexamic acid (TXA), often
take the form of lysine analogues that prevent
bleeding by interfering with the activation of
plasminogen to plasmin , a molecule re pon sible
for the degrad ation of fibrin clot . Aprotinin is
unique in that it promotes c lotting by inhibition
of erine proteases, includin g pia min , thereby
preventing the degrad ation of the pl as ma
protein compri s ing fibrin c lots.
The initial FDA approval was ba ed
primarily on two randomized, placebo-controlled
clinical trials. One study reported that 77 % of
patients who rece ived no bleeding prevention
therapy required at lea t one tran sfu sion dllling
or after the operative procedure ; among patients
who had received aproti nin , on ly 42% required
the administration of blood products?
The
3
second study showed similar result . However,
the author also noted the possibility of all ergic
reaction after chronic usage, as we ll as incidents
of kidn ey toxicity.
Although these adverse
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effects were sufficiently rare and manageable to
permit
drug
approval,
aprotmm
was
recommended for u e primarily m high risk
patients.
In the year following its approval,
aprotinin gained acceptance into the practice of
cardiac surgery. Over 70 tudie were conducted
to e tabli sh and confirm the efficacy of aprotinin
by measuring the blood product transfu ion
requirements of patients undergoing cardiac
bypa s procedures, with or without aproti nin. A
placebo-controlled,
double-blind
study
cond ucted by Bidstrup et al. , for example,
demonstrated a significant reduction in blood
unit required in a high do e aprotinin gro up
following cardiopu lmonary bypas .4
While
numerou studie
uch a this confim1ed it
e ffic acy, little hint of the ri sk of aproti nin was
found beyond the initially reported side effect .
Thi was due in large patt to the fact that the
primary endpoint of the majority of the e
studies, including that conducted by Bidstrup et
al. , were transfu ion requirements , and the
tudies were frequently not de igned or powered
to detect mortality benefit or specific adverse
outcomes. While donor blood requirements may
be used a an indicator of blood loss the e
studies failed to address ' patient im~ortant
outcomes' such as morbidity or mortality.
By 1998, the FDA had expanded the
indications for aprotinin use to all CABG
4
patient and its use burgeoned as it became the
mainstay of bleeding prevention therapy in
cardiac urgery. Thi was aided largely by it

newly expanded recommendation, a well as a
lack of other drugs indicated for thi s purpose, as
the ly ine analogue antifibrinolytics such as
TXA were initially developed to prevent
bleeding in other procedures and condition .5 For
everal years, the ri k of anaphylactic reaction
with repeated admini stration remained one of the
only ri sks identified with aprotinin use.
The fir t study to rai se concerns
regarding the safety of aprotinin was conducted
by Karkouti et al at the University of Toronto,
and wa published online ahead of print in
This
Transfusion on January 20, 2006.6
observational study employed a method known
as propen ity scoring to compare risk-variable
patients who received aprotinin or tranexamic
acid. Propensity scoring i a statistical technique
used to control for selection bias in observational
studies where treatment allocation is not random,
and involves detennining the probability, or
propensity score, of receiving a particular
treatment based on a number of background
variables, or covariates, which may plausibly
influence treatment as ignment. Whjle aprotinin
and TXA were found to be quite similar in
effectivene s with respect to transfusion
requirements, the former was associated with a
statistically significant increase in renal
dysfunction within the first postoperative week,
sometime requiring dialysis. 6 On January 26,
2006, a similar study conducted by Mangano et
al. was published in the New England Journal of
Medicine. 7
This multi-centre observational
study examined nearly 4500 patients who were
administered either aprotinin , aminocaproic acid,
tranexamic acid , or no treatment.
Through
propensity scoring and multivariate analysis,
they found that aprotinin was associated with a
significantly increased risk of renal failure ,
myocardial infarction, heart failure, stroke and
encephalopathy, while ACA and TXA were not
7
associated with these adverse effects. A
subsequent follow-up tudy by Mangano et al.
also demonstrated increa ed risk of long-term
8
mortality associated with aprotinin.
These two studies prompted the FDA to
initiate a year-long review of the safety of
aprotinin, and to convene a meeting of it
Advisory
Cardiovascular and Renal Drug
Commission on September 21 , 2006. The FDA

chose neither to amend the label on apro tinin nor
to iss ue any additional safety warnin gs
The
urrounding potential adver e effect .
primary outcome of the meeting was a reiteration
of the initial recommendation that aprotinin be
used only in high ri sk patients. In defending
their deci sion, FDA committee representatives
cited iss ues of tran sparency rel ated to an
unwillingness to release data on the part of
Mangano et al. 9 Mangano responded in a letter
to NEJM, indicating that although their data
release was initially offered with re trictions
related to patient confidentiality and independent
analysis, it was eventually offered without
re triction prior to the committee meeting and
following a lengthy delay in acknowledgment of
their data or requests by the FDA . 10 He further
indicated that, despite repeated requests, the
FDA infonned him that a review of hi s data was
unnecessary at that point. Six days following
adjournment of the meetings, however, Bayer
relea ed the troubling results of an observational
study it had commissioned.
These findings
demonstrated that the use of aprotinin led to an
increase in kidney damage, congestive heart
failure, stroke, and mortality, and quickly
triggered erious safety warning with re pect to
the drug. 11
Following the revelation s regarding the
safety of aprotinin, many sought to determine
what had gone wrong.
What they found ,
however, was even more di turbing than what
had already tran spired and rai sed seriou issues
with respect to manufacturer transparency and
deception regarding adverse drug effects. Bayer
hired a private contract research team to conduct
their observational study on the postoperative
complications of aprotinin use, and their findings
were similar to those of Mangano et al. 12 Further
inve tigation revealed that Bayer official were
given the preliminary re ults before the FDA
review meetings, yet neither the manufacturer
nor the private contract team had shared thi
information with the regulatory body. They
explained that an internal mistake resulted in the
delayed release of thi information . 13 However,
investigation into the body of evidence which
initially supported the efficacy of aprotinin
revealed that Bayer repeatedly funded numerou s
small trial which showed the drug to be
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effective, but were underpowered to show any
rare but seriou s adverse effects. Meta-analysis
later showed that on average these trials
referenced only 20 % of the preceding reports;
only 15 % referenced the largest trial , which is
considered to be central to the evidence
urrounding aprotinin. 14

Ethical Analysis
The aprotinin ca e serve to hi ghli ght numerous
ethical i sues with drug regulation and safety a
they pertain to the pharmace utical indu. try.
While public intere t and patient safety should be
central pri oritie in all healthcare activiti es, these
can be overlooked or ignored by pharmaceutical
companies in favor of drug marketing. However,
in this instance, ethical i ues are raised not only
by Bayer's actions, but also by those of the FDA
and the researchers who ounded the alarm .
FDA: According to Man gano , the FDA did not
respond to his repeated requests for data review
prior to upholding the apro tinin label, citing it
was unnecessary. In hi response to the FDA 's
decision, Man gano stated, "The FDA and its
Advisory Committee sho uld take a conservative,
protective stance when independent ev idence
regardin g dru g safety presents itself. In stead,
they appear to be protecting the drug rather than
11
the patient. "
While ethical discuss ion centered on dru g
regulation most often foc uses on the behavior of
pharmaceutical companies, the aforementi oned
interacti ons between Mangano and the FDA call
into question the prioriti e of the regulating body
as well. Whil e the FDA did requ est the data
from the Mangano study upon convenin g it
Advisory Com mi ss ion, it appear as if the FDA
did not make every effo rt to obtain the data via
di scus ion with Mangano before judging the
safety of the dru g. This raises questions a to the
efforts of the FDA and the nature of the
influence of ph arm aceuti cal co mpani es on their
regulatory body.
Mangano : While the researcher did offer the
original . tudy data to the FDA, there appeared to
be initial resistance to do so in th at data release
was contingent upon several restnctJOns
includin g pati ent confide nti ality and independent
data analysis.
This rai e
the iss ue of
tran sparency in research , and the situation in
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which researchers should be encouraged or
obligated to share their data and their anal~tical
methods.
Methodological transparency IS . of
particular importance in observational stud1es
where treatment allocation is not randomly
assigned and certain analytical s trat~gies are
required in order to minimize known b1ases and
approach a true evaluation of effect. Often these
are the only means by which critical drug safety
issues can be evalu ated . Thu s transparency
becomes a central value in research ethics.
However, the concept of transparency itself
rai e further ethical i sues, as the obligation the
release indi vidual-level data may conflict with
the value of privacy and anonymity.
Bayer:
Bayer face the erious charge of
withholding inform ation garnered from a
privately conducted tudy at the time of the FDA
co mmi sion. This goes beyond the concept of
tran parency and encroaches on honesty, which
mu t undoubtedl y be a central value in all
research acti vities. It ha become clear that
Baye r became aware of at least the preliminary
resu It of the study , yet they did not di sclose thi s
information to the FDA Advi ory Comrni ion in
a timely manner. Dru g afety analy es are often
an is ue because we rely on pharmaceutical
companie to fund the tudie necessary to assess
safety ; however, when they have a vested
intere t in the lucrative s ucce of their product,
it i difficult to expect them to fund or disclo e
the re ult of tudi es that might disc redit their
product or jeopardi ze it succe .
Bayer'
Finally, and most
ubtly
inve Li gation of the effectiveness of aprotmm
remains in tark co ntrast with the principle of
clinical eq uipoise. Thi principle tates that
rando mi zed control trials can only be conducted
ethi cally when tru e di agreement exi t as to the
effectiveness of one treatment compared to
another. In placebo-controlled studie , it is only
ethical to admini ster no treatment (or a placebo)
whe~ no proven treatment exi ts.
Bayer
contmued to fund placebo-controlled RCTs
de pi~e. the prev iou
literature supporting
aprotmm as an effective treatment for decrea ino
tran fu sion requirements.
In hind ight, thi~
appear to have been done in order to build the
body of evidence supporting thi s therapy, and to
continue to show effectiveness without bein g

able to identify adverse effect a ociated with
it
admini tration.
These
tudie , while
ufficiently powered to detect ignificance of
efficacy, were for the mo t part too mall to have
a high likelihood of howing serious and rare
side effects. These actions further contributed to
the skewed view of aprotinin held by both the
public and the medical community, and to its
longtime u e de pite its dangers.

3.

4.

Conclusion
The protracted length of time between the
approval of aprotinin for the prevention of
exce ive bleeding during coronary artery bypa
grafting and the revelation of drug afety
concern indicates a need to refine the process of
drug
afety revtew .
The ethical tssues
highlighted
by
the
action
of Bayer
Pharmaceutical ,
the
Food
and
Drug
Admini tration , and the drug researchers indicate
that drug safety is not influenced olely by the
philo ophies of pharmaceutical corporation , but
instead it involves complex political and
procedural
interactions
between
the
pharmaceutical companie , the regulating body,
and drug inve tigators. We have indicated a
fundamental requirement for transparency as it
pertain to all studies asse sing dntg afety,
particularly on the part of the pharmaceutical
compante . As observational tudies are often
the only mean s by which we can assess longterm drug safety, it i al o important that they be
tran parent and sufficiently powered to detect
long term morbidity and mortality. While the
aprotinin aga repre ent a very recent example,
other drugs including flecainide acetate
(Tambocor) and ro iglitazone (Avandia) have
rai ed imilar i sue in the past decade. Major
change are required to refine the evaluation and
monitoring of pharmaceutical products following
regulatory approval and widespread use. These
acti vi tie are critical to treatment effecti venes
and patient safety.
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Heart Health or Hype? Exploring the effect of diet trends on cardiovascular disease
Jonathan Klein, Medicine 2010 and Laura Hinz, Medicine 2011
Reviewed by Dr. Lynn Bergin
Certain foods have been touted a prov idi ng pecia l benefits in preve nting cardiova cul ar di. ease. We reviewed the
literature upporting cardi oprotecti ve effec ts from cranberri es, choco late, dairy foods, and omega-3 fatty ac id · T o
varying degrees, all fo ur of the e ca tegorie of food prov ide demonstra ted be nefi t for heart health . For each food
in vesti ga ted, we prov ided insight into how they ca n be incorp orated into a hea lth y li fe ty le along w ith o rne caveats
aga in t their overuse. A balanced, nutri tious diet including orne of the e food , combined with an acti ve life ty le, can
provide proven benefi ts for cardiova cul ar hea lth .

Introduction
The importance of eating a balanced di et and
engaging in regul ar exerc i e for the maintenance
of good health is generally accepted as common
ense and is upported by ri go rou s sc ientifi c
1
in vesti gati on. Obe ity and inac tt vtty rate
continue to ri e teadil y, however, bringing with
them a ho t of di sorder such a diabetes mellitu
and cardiova cul ar di ease (CVD). In the face of
increa ed CVD incidence, many food have been
touted as being espec iall y good for the heart. In
thi article, we in ve ti gate the bi ochemi stry and
ev idence fo r the cardi o protective effect of
cranberries, choco late, dairy foods, and omega-3
fatty acid , whi ch have all received attenti on for
their potenti all y heart health y pro perti es.
Cranberries
Evidence and Biochemistry: C ranberri es have
been pro moted for putati ve wide-rangin g health
benefits, o much o that the jo urn al Criti cal
Reviews in Food Science and N utriti on devoted
an entire 2002 iss ue to ex to lling the fruit 's
2
virtue . Fro m preventing urinary tract infecti ons
to pro tectin g against gastri c ul cer 3 to reduc in g
4
th e ri sk of cardi ac events, cranberri es have been
credited fo r providin g ignificant hea lth bene fit
beyond th ose o f other fruit .
Several large
tudi es, including the
5
lNTERHEART tud y, have shown signifi cant
health benefits from di et hi gh in fruits and
6
vegetables, such as th e Mediterranean Oi et.
Though many mechani ms for the e re ults have
been proposed, much attention has focu ed on a
class of compounds called fl avonoid , whi ch are
present in hi gh concentrati ons in cranberri es and
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other fruit .7 Flavo noid
are a group of
mo lecul es with a common diphenylpropane (C6C3-C6) mo iety, which contain two aromatic
ring linked by a ix-member ring. There are ix
different categories of fl avonoids characterized
by variati on in the central ring. 8 Cranberries
co ntain many different flavonoid classes
inc luding
fl avo nol ,
fl avan- 3-ols,
and
anthocyanin .9
Flavo noids have been identified as
cardi o protecti ve co mpound
due to their
11
antiox idant effect . Substantial ev idence has
demon trated that ox idation of low den ity
lipoprotein
(LDL,
the
o-called
"bad
cho le tero l") co nttibute to atheroscl ero is, one
o f the main predicti ve fac tors of heart attack
12
and troke .
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Figure l:. Structure of lb vone (2-pheny lchr men-4-o ne),
the cherru ca l backbone o f the ll av noid . Additi on of
fun ctional groups to tl avo nt: produce different llav noid .
For exa mple, reducing the ketone group to a hydrox 1
yields a llavo nol. 10
Y

Oxidized LDL is preferentially taken up into
macrophage and foam cells), which are major
constituents of atherosclerotic plaques. 13 By
reducing the oxidation of LDL, flavonoids help
prevent this accumulation of plaque, decreasing
morbidity and mortality from CV di sease. 14 It
eems that only small amounts of fl avonoids are
needed to achieve their beneficial effects, so
even occasional consumption of cranberries may
be cardioprotective. 15
Ruel and Couillard have also shown that
there i so me evidence for cranberrie improving
plasma lipid profiles, another strong predictor of
cardiovascular disease. The evidence suggest
that cranberries may be able to increase HDL
and decrea e LDL levels in the blood, but some
tudies have failed to show a change in serum
lipid levels.7
Verdict: Cranberries seem to confer significant
benefits on cardiovascular health, mostly through
flavonoid-mediated inhibition of oxidation of
LDL. Including fresh cranberries or cranberry
juice in the diet can reduce the ri k of
atherosclerosis and subsequent events such as
troke or infarction. However, these benefits
may not be exclusive to cranberries, as research
has shown similar outcomes with diet high in
other fruits and vegetables (such as the
Mediterranean diet). Con umer should also be
wary of the advertised benefits of cranberry
juice. While these juices do contain flavonoids
and other beneficial compounds, inve tigators
exclu ively studied the benefits of low-calorie
juices. Mo t commercial juices are high in sugar,
which can contribute to obesity and other
associated health problem . For an effective
public-health campaign to be built around
cranberry juice, it mu st be explicit th at fre h
cranberries and low-calorie juices will confer the
greatest health benefits. All in all, the data is
strong suggesting that adding cranberrie to an
already balanced di et may reduce the onset of
cardiovascular symptoms.

Chocolate
Evidence and Biochemistry: Many news outlets
have publicized studies demonstrating the
16 18
benefits of chocolate consumption. - While the
reports have been careful to warn against gorging
on chocolate bars in an effort to stave off

atherosclerosis, many people may still be
tempted to add large amount of chocolate to
their diet, possibly believ ing that protecting their
hearts is outweighs the ri sks of excessive junk
food consumpti on.
Studies on chocolate and cardiovasc ul ar
di sease have focused on the effects of dark
.
. 19 Th e
chocolate and cocoa consumptiOn
protective mechanism is similar to that of
cranberries, with fl avonoids acting as the
primary cardioprotecti ve agent. Chocolate
contains large amounts of catechin , which are
flavan-3-ol
fl avo noid
compound ,
and
20 2 1
procyanidins, another ci a
of flavonoids. The mech anism mimics that of cranberries, with
an increa e in anti-oxidant effects inhibiting
LDL oxidation and preventing formation of
arterial plaques.
Studies have also demonstrated that
chocolate and cocoa consumption can raise
levels of high den ity lipoproteins (HDL, the
"good cholesterol"), which has been shown to
22
decreased susceptibility to cardi ac events.
Increased HDL levels have been hypothesized to
suppress LDL oxidation by one of several
mechanisms including inhibition of monocyte
chemotaxi
leading
to
decreased
23
atherosclerosis and direct hydrolysis of lipid
4
peroxide? Some studie , however, have failed
to demonstrate ignificant change in HDL:LDL
ratios, o chocolate alone hould not be used to
treat lipid disorders. An average increase in HDL
level of 4% and 8% longer lag time in LDL
oxidation were observed in patients on an
average American diet supplemented with 16g of
dark chocolate and 22g of cocoa powder per
day. 19
Verdict: Medical consensus holds th at chocolate
and cocoa can protect against cardiovascular
di sease, likely via flavonoid-mediated LDL
antioxidation and increased HDL levels.
However, the observed effects on the serum
lipids were relatively minor -hardly ufficient to
counter the fact that chocolate i a high-fat, hi ghsugar food lacking the overall nuttition al value
of other rich flavonoid sources such as fruits and
vegetables. Expetimental studies focu sed only on
dark chocolate and cocoa consumption (not other
varieties, like milk chocolate) and were careful
to study diet similar to a standard American diet
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in nutritional value and calori c intake. Thu s,
adding chocolate to the diet without eliminating
an equi valent source of calori es and maintainin g
proper nutriti on has not been hown to improve
health and intui tively seems likely to contribute
to poor health th ro ugh increased weight and
adi pose bu ild- up. Our recommendation is that
dark chocolate or cocoa may be consumed to
prevent heart di sease, but onl y a part of a
balanced, nutritional diet. While (arguably) less
enjoyable, it may be more beneficial to overall
health to seek a differe nt so urce of fl avo noids,
such a frui ts and vegetabl es.

Dairy Products
Evidence: Milk con um ption has traditi onall y
been associated with increased cardi ova c ular
disease due to its high cho lestero l and satu rated
fat content, 25 which have been cau all y linked to
atherosclerosi . 12
However,
everal
epide miologic
studi e
have demonstrated
reduced risk of athero clerosis with inc reased
Further
evidence
fo r
milk
intake. 26 -27
cardi oprotecti ve effects of dairy foo ds co mes
fro m the o-called "French paradox;" the typical
diet in France is high in saturated fat and
cholesterol, but the citizens tend to have a lower
28
incidence of heart disease. The e data suggest
th at further co n ide rati on of dairy product a
protective again st cardi ovascul ar d i ea e is
warranted.
One
hypoth esis
fo r
milk ' s
cardi oprotection is that it reduce su ceptibility
to the metabolic syndro me, whi ch can lead to
cardi ovascular di sease. 28 The World Health
Organization defines metabo li c yndro me as
glucose into lerance, im paired glucose to lerance
or di abetes mellitus and/or in sulin re i Lance
together with two or more of: blood pre . ure
above 140/90, hi gh pl as ma tri glyceride and/or
low
HDL,
central
obesity
and
lb
29
m1 croa ummun a.
Several studi es have hown in verse
relati onships between dairy foo d consumpti on
and all as pects of the metaboli c syndro me.30 -32
The e studies have shown that milk has a
protecti ve effect in both men and wo men and
across populati ons of differe nt ethniciti es and
nati onaliti es. Th e incide nce of type II di abetes
mellitus, one of the co mponents of the metaboli c
0

0

0
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syndrome and a di sease also characteri zed by
insulin resistance, was demonstrated to decrease
with hi gher dairy intake. The effect was even
larger if the study participants consumed only
28 33
low-fa t dau y products. ·
.
Dairy foo ds may also prevent weight
gain, and might even promote loss of abdominal
fat. 34 This would , in tum , reduce the risk of
obesity leading to onset of metabolic syndrome,
which wo ul d prevent the resultant cardiovascular
disease. One explanatio n fo r this effect holds that
dietary calcium may play a role in regulation of
energy metabolism.28 Dairy foods can al o have
antih ypertensive effect , as eating 35 or more
ervin gs of dairy per week halved the 10-year
ri k of developing hypertension as compared to
eatin g 10 or fewe r serving in the CARDIA
stud y. 30 Thi effect may result from peptide
produced by lactic acid bacteri a present in milk
product inhibiting ACE enzyme and endothelin
re lease, two kn own anti"h ypertenstve agents. 35-36
Verdict: Even though dairy foo ds contain
ignificant amount of CVD-pro moting fat and
chole terol, the ev idence uggests that dairy
products are actu ally cardi oprotecti ve. The
dramati c re ult of the C ARDIA tud y how
significant anti hypertensive effec ts, though it i
unrealistic to ex pect peopl e who would not
otherw i e do so to eat 35 or more ervings of
dairy foo d per week. However, even moderately
increas in g dairy co nsumpti on can be beneficial.
Dairy food al o pl ay an important role in
protecti on fro m metabolic syndrome and type II
di abete . Low fa t and skim milk and yogurt seem
to have the most pro nounced effects, and people
wishing to increase their dairy con umption
should foc u on the e foods. Though the
evidence is stro ng for dairy products' benefits, it
is important to re member that dairy foo ds will
not pro tect against C VD in the ab ence of other
interventi ons like a balanced diet and acti ve
lifestyle.
0

0

r

Omega-3 fatty acids
Evidence: Of all the dietary elements claimin bo
cardiovascular benefit , few have garnered more
attention than omega 3 fatty ac ids. Egg , bread,
yog urt and other foods are fo rtif ied with the e
compounds and display attention -grabbin g labels
touting their hi gh levels of o mega-3. Di etar y

0

II

~c - c - c-c - c = c - c - c=c - c- c = c - c - c = c - c -c= c -c- c

HO
Figure 2: Eicosapentanoic acid, an example of an omega-3 fatty acid. Note that the th ird-last carbon i invo l ved in a
39
double bond.

supplements containing omega-3 ' s are also bein g
marketed with promises to deli ver improve ment
in health .37
Omega-3 fatty acid are e ential fatty
acid naturally present in fish, flaxseed, walnuts,
canola oil , and soybean oil. They are o named
because they are characteri zed by a double bond
beginnin g at the third-last carbon atom in their
chain , the third carbon from the "omega" end of
the chain. The three main omega-3 fatty acids
consumed
are
alpha-linolenic
ac id,
eicosapentaenoic acid and docosahexaenoic
acid. 38
Omega-3
fatty
acids
have
been
demo nstrated
to
exert
anti atherogenic,
antithro mbotic, and anti arrh ythmic effects, all of
which contribute to their preventi on of
40
cardiovascular disease . In vesti gatio ns using
many different de igns have linked omega-3
fatty acid and fi sh consumptio n to reductions in
cardiovascular disease. Epidemiologic studies
include the Health Professional Follow Up
41
2
study and the Nurses Health Studl
which
fo llowed 45 ,722 and 76,283 subj ects for average
follow up time of 14 and 10 years, res pecti vely.
The Nurses Health Study showed a relati ve risk
of fatal i chemic heart disease of 0.55 for the
cohort with the hi ghest consumptio n of omega3' s versus the gro up with the lowe t
consumption. Other studie and meta-analyse
have demonstrated in verse relati on hip between
omega-3 consumption and mortality, both allcause mortality and that from cardiova cular
di sease (coronary artery di sease, MI, stroke,
etc.).43-45
Given the benefit to heart health
demonstrated by these studies, it is not surprising
that omega-3' have received huge publi city and
are potenti ally exploited by dubi ous companies
and products. A search fo r "o mega 3" on the
popular search-engine www .ask.com yi elded
links to websites claiming extra benefits fo r such
46
products as Norwegian " virgin almon oil."

Other ites pro mote "clean" and " natural"
omega-3 sources 47 and oils deri ved fro m "gently
pressed" ources. 48 Such products typicall y co me
in pill fo rm with reco mmended do es of up to 3
per day, ensurin g a hi gh cost fo r their co ntinu ed
use.
Verdict: A reso unding yes. The evidence is
extremely strong that including fish and other
o mega-3 sources in the di et, even in moderate
amo unts, can prov ide maj or benefits in reducti o n
of cardi ovascular disease. However, there is a
potential for ex ploitation and fa l e claims to
abound due to lack of public understanding.
Claims of special efficacy fro m certain types or
sources of o mega-3 and claims th at intuiti ve ly
unhealth y foo ds like bacon are actually health y
should be ignored. Nevertheless, fish and other
omega-3 fo rtified foods like eggs and yogurt
should be added to the diet of heart-conscious
people. The Am erican Heart Associatio n and
World Health Organi zation both recommend two
servin g of fi sh per week, especially oily fi h
like salmon , tuna, and trout. Diets such as the
49
are good sources of
Mediterranean diet
guidance for incorporating o mega-3 fatty acids
into a health y di et.

Conclusion
Diet plays a powerful role in cardi ovascular
health , but this will not come as news to most
people. However, certain foo ds seem to confer
more benefit than others, whether by changin g
lipid profiles,
moderating the metaboli c
syndrom e, anti-thro mbotic effects, or other
mechanisms. Stro ng ev idence backs cranberrie ,
dairy foods, chocolate, and o mega-3 fatty acids
as pro tecti ve against cardi ova cular disea e. A
few studies received funding or other upport
fro m corporations with interests in the
. 1 f or b"1ase .
reS u lts 3, 11 .30 w h"IC h create a potentia
However, the vast maj ority of tudi es cited in
this paper did not declare any competing
interests and the evidence remains stro no
b
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supporting the cardioprotecti ve effects of the
aforementioned food .
These effec ts demonstrate that what we
eat can powerfull y impact the health of our
hearts. However, it is important not to overstate
the impacts that the e foods can deliver. After
surveyin g the ev idence, a Starbucks Mocha Latte
may seem to be a new "superfood"- after all, it
contains choco late and caffeine fo r anti ox idants
milk fo r calcium, and health y fa ts. Bu t tha~
doesn' t cancel out the sugar and unhealth y fa t
assoc iated with tho e beneficial compound . No
single food will prevent heart di ease nor i
adherence to every new guideline required to be
protected, but modem researc h continue to
support Hippocrate ' idea that foo d ha the
power to heal. Regular exerci e and a balanced
diet incl uding so me of the food di scussed in thi s
article will go a long way toward maintainin g a
healthy heart.
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History of Medicine
History of the Circulatory System: discovery of the basics
Adam Garber, Medicine 2010 and Michael Livingston, Medicine 2011
Reviewed by Dr. Vi vian McAlister
T oday, the fi eld of cardi ology i understood a a highl y evo l ved and mature pec ialty of medicine. H owever, the
journey toward our current gr a p on the subject ha been a long one. T he discovery of the most basi c heart phy iology
and anatomy ha a hi Lory of more than two mill enni a. T hi s paper d i cus e the development of the most fundamental
principles of heart phy iology and anatomy whi le outli nin g the influential contex t of their ori gin .

The fie ld of cardi ology ha lo ng been perceived
as a hi ghl y sophi ticated are na of understandin g
wi th ph y iologically intri cate pro ble m and
technologically advanced oluti ons. And though
it i j u t that, it was not alway o. In the greater
timeline, cardi ology a a medical pecialty i till
in it in fa ncy. More o, cardi othoracic urgery
remained a fie ld unborn until after World W ar II,
making it the tardiest of urgical specialties by
1
twenty year . The stud y of the human heart in
general ha had a much longer history with
fa c in atin g accelerati on , tediou plateaus, and ,
at times, di appointing regressions. But the
hi story that is di cus ed herein is the history of
that part of cardi ology that most people, scie nti t
or not, take for granted a obvious knowledge;
this is the understanding of the most ba ic
principl es of the circulatory system.
I begin at the end o f thi s hi story by
ummari zing its acco mpli shment. The heart i a
pump. lt contain four chamber . The ri ght ide
o f the heart pump bl ood to the lun g where it
pi ck up oxygen and then enter the left ide of
the heart. The oxygen-ri ch bl ood in the left side
o f the heart i separated fro m the oxygen-poo r
blood in the ri ght ide of th e heart by the
interventri cul ar septum . The oxygen-ri c h blood
is pumped throu gh the le ft ide o f heart to th e
entire body by arteri es where it uppli es the
di fferent ti s ues with oxygen. Oxygen exchange
occurs in the small e t ve se ls called capillari es
and oxygen poor bl ood ubsequ ently is carri ed
2
bac k to the ri ght side of the heart by vein .
The mo t bas ic princ ipl es o f the
circ ulatory system took thousands of year to
uncover. An E gyptian papyru datin g back to
l500BC correctl y correlated the character and
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frequency of the pul e with the patient's health
status. Hippocrate (460-355BC) and his pupils
also drew acc urate co nclusion regarding the
nature of blood fl ow. One pupil described the
perpetual movement of blood " with courses of
ri ver returning to the ir ources after a passage
through numerou channel ". 3 However, this
concept of circul arity wo uld only be confirmed
two millenni a later by William Harvey. It wa
Ari totl e, the anato mi t, philo o pher, and knowit-all of the time who began the di ruption of
cientific under tanding of the heart and its
y tern. While orne of hi physiological ideas
bore orne value, he al o committed the
academic di ervice of attributing the eat of
body intelligence' and the ource of body heat to
4
the herut . Such exaggeration of the heart's
fun cti on in the body was mirrored by
Erasistratu (c. 3 10-240BC) who first described
the heart' val ve , and ex pla ined that air entered
the heart fro m the lung
where it was
transformed into ' pneuma', the vital pirit, 'a
most ubtle vapor' to be carri ed to the body by
1
arterie . Only ve in , he eiToneous ly conceived ,
contained blood.
So, fo r a peri od of 500 year little
advance was made in the under tandin co- of the
c irculatory syste m. However, the under tanding
o f our world and all thing in it was forever
changed w ith the birth of Chri ti anity and it
populari zation. Indeed, the nex t advance ment in
circul atory ph ys iology came from Gale n (c. AD
130-200), whose work was viewed favo urably
by the Church. Galen, though not Chri ti an, was
monothei. tic and hi wor hip o f o ne god ,
Aesculaplll s, the god of medi cine, haped hi
theories in uch a way th at they were compatible

with the vi ews of th e Church. The Church was,
at the time, fi ghting Roman polythei m and so
Galen' s worship of a si ngle God who created all
things fo r a purpose was agreeable enough. 1
ln brief, Galen fo und th at arterie
contained blood, in tead of air a had been the
belief to that point. He conceived of two
ystems: the venous system whi ch was
nutritionally relevant, and the arteri al system,
which was responsible fo r body heat. Included in
his theories are the belief in the existence of
pneuma, the vital spirit on which life depends as
well a two other spirit , the ' animal pirit' and
the ' natural spirits' . Galen falsely connected
these two ystems of the ri ght and left heart by
supposed pores in the interventri cular eptum. 1•4
Galen'
theories were more thorou gh and
complex than detailed in this essay. His views
were intricate enough for the critical scientist,
compatible enough with the Church, and
mystical such
that it enre uraged the
philo opher's under tanding of the heart as the
seat of the soul. As a result, his views went
largely unqu estioned fo r a staggering 1500
years !
The fir t ph ysician to question Galen '
views was Ibn An-Nafis (12 10-88), whose work
made the first reference to the pulmonary
circulation. However, thi s kn owledge was likely
lo t until this same findin g was independently
di covered three centuri es later by Servetu s, a
Unitarian, who was rewarded for his science and
his anti-Protestant beli ef by John Calvin in
Geneva, who had him placed on a stake and
1
burnt to the core. The initi al anatomical
understandin gs of the heart were dispersed, lo t,
or destroyed purpo efully and, throu ghout the
Dark Age , human dissecti on was either
di sallowed or difficult to carry out due to certain
5
impo ed ecclesia ti cal edicts. Leonardo da
Vinci (1452-151 9) took great interest in the
anatomical structure and ph ysiological workings
of the heart. He correctly drew the heart with
four chambers and, through experiments,
described the mechanism by whi ch the aortic
valve closed. 6 Andreas Vesalius (151 4-64) also
possessed a passion for dissection and partook in
the illegal yet common , practice of bodysnatching. In his work, "De Humani Corpori
Fabrica", he carefully, but strongly, questi oned

Galen's view , which were taught in the chools
of medicine du ri ng his time.
With Galen's views begi nnin g to turn
obsolete, many ph ysiological questions of the
heart were reopened. In 1574, Fabriciu of
Aqu apendente (1537- 16 19), publi hed "De
Venarum Osteolis" which examined the valves
of veins. He aptl y de cri bed the valves a ' the
little doors of the veins' and pro posed that they
'delay the blood and so prevent the whole of it
4
flowing to the feet. .. and collecting there' . But it
was Willi am Harvey (15 78- 1657) who fin all y
deconstructed
the
false
views of the
cardiovascular system. Hi s, "De Motu Cordis", a
short book dedicated to King Charle I,
compared the ' ki ng in hi s kingdom' to the heart
1
in the contex t of th e body. T his wise maneuver,
which praised the Kin g whom he and many
admired, perhaps aided in his avo idance of harm
fo r hi s publication of contrary views. Th ro ugh
his lectures and in his publication, he explained
that blood pumps with ventricular contraction
thro ugh the lungs back to the heart and th en
through the body where it ' passe thro ugh pores
in the flesh' and returns fro m the periphery
through veins increasin g in size as they approach
the h eart. ~ He specified that blood moves, ' as it
were, in a circle' and ' th is is the only reason fo r
4
the motion and beat of th e heart' . He
emphasized that the heart is no other thing but a
pump as if to crush the spiritu alistic functions
impo ed on the heart until th at time. Finally,
Marcello Malpi ghi (1628- 1694), Jacob van
Swammerdam (1637- 1680), and Anthony van
Leeuwenhoek (1632 -1723) used the microscope
to ex plain the shape of the red blood cell and the
capillary networks that fo rm the connection
between arterioles and venules.4
So, over a great many years the myth of
the heart were dispelled and the truth came to be
accepted like in mo t cases of di covery, slowly
and with much dissent. Yet the heart remai ns an
etern al symbol. A ubiquitous metaphori cal fo rce
made reference to by the holiest of books and by
the most lucrati ve of co mmercial recordin g
artists. In Genes i 6:6 God i described a
possessing a symbolic ' heart' when he decides
that a great flood is in order, " And the LORD
was orry that He had made man on the earth
and He was gri eved in His heart" . 7 God who has'

UWOMJ 77(2) 2008 23

no other body part, but perh ap for a guiding
' hand ', must also pos e a ' heart', an enigmatic
box of emotion. M ore comicall y, Tom W aits, the
guttural crooner, explains that he has a "bad live r
and a broken heaLt" .8 While cocktails and the
like may have done the job on hi s li ver, it was
an e motional cocktail of ort that hanned hi s
heart. The li ver's pro blem i ph ys iological but
the heart's is of a different nature. The ' heart' a
a human-constructed ymbo l is an entity whi ch
attempt to tran cend it physio logical function
and to uch on the intangible a pects of what it i
to be hu man. T hen is it so urprising that with
all of this attac hed ymbo li sm, th e academi c
uncoverin g of the function of the heart too k a
long a it di d? It wa a lot to lose and yet, the
ym bo l ha never been lost at all.
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Medicine and the Internet

Computer-assisted learning-teaching clinical skills in cardiology
Jordan Glicksman, Medicine 2010. Pencilla Lang, Medicine 2011, and
Dr. Kevin Fung, Department of Otolaryngology
Reviewed by Dr. David Masse/
Cardiology i a diver e and ever-expanding field of medicine. Medical trainees mu t master a wide variety of skill
and knowledge in order to become proficient at managi ng patient with cardiovasc ul ar co nditi ons. Comp uter-assisted
learnin g has the potential to enhance medical teac hing in card iol ogy by providing tudents with an enriching
interactive learnin g environment.

During medical school , student are expected to
develop a trong foundation of clinical skills. In
many centers tandardized patients are used to
teach and evaluate students as they have been
hown to be an effective teaching method.
Cardiology, like many areas of medicine, is a
diverse and ever-expanding field. Advances in
technology have made many tool available to
clinician to diagnose and manage patients with
cardiova cular
conditions.
Despite
the
availability
of
equipment
such
as
electrocardiograms (ECG), echocardiograms
(ECHO), physicians till rely heavily on basic
clinical skills uch as history and physical exam
1
to determine the nature of a patient's illness •
While traditional teaching method are helpful
fo r teaching students basic eli nical skills,
multimedia computer technologies provide
students in the 21 t century with an opportunity
to refine their talents.

The Current Use of Multimedia Teaching
Tools
Medical educators already ultilize multimedia
computer technologies to provide students with
increased exposure in their respective field . The
Computer-Ass isted Learning in Pediatrics
Program (CLIPP) has already been implemented
to augment medical education in pediatric _2
CLIPP is a computer-assisted learning (CAL)
program that provides students with a
multimedia experience to case-based learning.
Programs like CLIPP are gaining popularity, as
they allow students to learn at their own pace.
This can allow for tudents to learn at a time and

location that is convenient for them, as long as
there is a co mputer available to work at.

Advantages of CAL in Cardiology Clinical
Skills Teaching
CAL application are of particular value 111
cardiology teaching due to their ability to
provide students with information in an
interactive manner. In a traditional teaching
etting, students may be taught during a didactic
teaching seminar (and subsequently memorize)
that an aortic stenosis murmur is a sys tolic
ere cendo-decrescendo
murmur.
This
information may be reinforced in a clinical
methods teaching seminar. However, without
actually hearing the sound themselve , can
tudents truly appreciate the sound of such a
murmur? Furthem1ore, will students be able to
apply this knowledge to a patient that present to
them during their training or in their future
practice?
CAL allows students to learn in a truly
enriched self-directed learning environment.
Physical findings such as au cultation may be
conveyed as they would naturally be ob erved by
the student. Heart sound from patients with real
findings may be recorded with electronic
stethosco pes and then can be incorporated into
the CAL program. Additionally, the programs
may make use of other tools such as ECHO and
ECG findings to allow the learner to correlate a
patient's findings into a broader picture and help
reinforce the content.
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Costs of Implementation
While the multimedia approach that CAL offers
is exciting, as with any new technology, cost can
be concernin g. Nevertheless, widespread use of
CAL modules can be very cost-effecti ve For
example, in 2005 , the average development cost
per CLIPP ca e session was approximately $6. 2
Thi s amount will decrea e as the number of
students using the program increase . Replac ing
traditi onal teac hing method with CAL has the
potential to free up the time of medical school
lecturer to teach in other capacities, such a
small group ses ion . Furthermore, CAL has the
potential to enhance teaching at di stant locati ons
uch as satelli te campu es, rural setting and in
developing nati ons.

CAL and Other Learning Methods
Adult have been how n to learn optimally in
self-directed learnin g enviro nments? As a result,
there has been a shi ft away fro m traditi onal
lecture and eminar-based teaching and towards
the implementation of more
elf-directed
learning in medical school . In addition to the
use of multimed ia modalities, CAL can help
guide learning thro ugh other fea tures uch a
qui zzes and learnin g game . In fac t, many
in fo rmal fo rums fo r CAL have already been
created by students and in structor . For example,
it i po sible to find video in structi ons for
various as pect of the clini cal examin ati on on
YouTube ® and perso nal webpages. A more
profes ional fo rum wo uld allow tudents to
better capitali ze o n CAL's advantage .
Currentl y, th ere i debate a to the effecti venes
of CA L as a teachin g modality. Several studi e
have co mpared the use of C AL to other modes of
learn ing. So me of the e tudies how th al there i
no significant di ffe rence in knowl edge and s!Ull
retenti on between those taught didactica ll y or by
seminar when co mpared to tho e taught by
co mputer teaching modules, while so me tudi e
ugge t that other fo m1 s of leac hin g (e.g. didactic
Iecture ) are tt'll supen.or. 2 · ,_(. 7

The Future of CAL
While research continu es to asse s the
effecti venes of CA L in medical educati on, this
new learning tool is a ri sin g fo rm of medical
teachin g. Th e Assoc iati o n of Am eri can Medi cal
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Co lleges (AAMC) has established MedEd
Portal, a peer-reviewed collection of online
teaching tools. This resource contains a database
of learning resources that include tutorials,
virtu al pati ent , and case-based learning among
8
other medical education resources. Not only
does the MedEd Portal provide easy access to
CAL modules, but it also provides incentive to
acade mi c ph ysicians to create more CAL tools
th ro ugh recogmt10n
as a peer-reviewed
publication. Initiatives such as thi s will likely
increa e the productio n of CAL module .
The u e of computer-based teaching in medicine
has the potenti al to change the way medicine is
taught to both current and future generations.
Between the multimedi a capabilities of CAL,
enh ancements over current learning modalities
and increa ed recognition for publishing CAL
modules there appears to be a bright future for
co mputer-a sisted learning.
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Medicine and the Law
Medical Malpractice Litigation: Myth or Growing Crisis?
Abdullah Alabousi, Medicine 2011
Reviewed by Dr. Mark Speechley
One of the most ta lked about is ues in hea lth care, and one th at receives much media coverage and public attention, is
medical malpractice liti gati on. Opinions on how well thi s liti gati o n sys te m functions differ, o metimes starkl y,
depending on who is being asked. In o rder to full y apprec iate the exte nt a nd co mplex ity of medical malpractice
liti gation this paper will con ider the de finiti o n of med ica l ma lpracti ce as well a the laws and proced ures followed in
Canada. M oreover, tre nds in ma lpracti ce law uits for practi c ing ph y ic ian s in the field of Card io logy will be u ed a a
ca e study. Hopefull y, by introduc ing the key orga ni zation and parti es in volved a nd the important tre nd s and
indicator to watch, thi paper will help the reader be more informed as a co mpl ex debate unfo lds on the effec ti ve ness
of the c urrent syste m.

One of the most talked about issues in health
care, and one that receives much media coverage
and public attention, is medical malpractice
litigation. Broadly, litigation refers to the u e of
the courts to enforce a right, and request a
remedy, by one party against another. In the
context of medical malpractice litigation, the
legal 'right' being enforced is the right of the
public to competent medical care - care that is
free of medical errors that could rea onably have
been avoided. 1
Opinions on how well thi sy tern
functions to protect this right differ, sometime
starkly, depending on who is being asked. For
example, some physicians view such legal
action "a random events that visit unwarranted
expense and emotional pain on competent,
hardworking practitioners". 1 Similarly, within
the North American healthcare industry (the
hospital sector and insurance providers) there is
wide agreement that medical malpractice
lawsuits have become more of a burden than a
way to ensure patient safety and punish errors
and carelessness. Even some observers from
outside the medical system express their concern
that medical malpractice cases have been altered
into some form of a "lawsuit lottery" whereby a
few patients receive hefty compensation, while
no reimbursement is given to the majority of
1
patients injured by medical errors. Nonetheless,
lawyers and the public, even with all the
imperfections and equity problems, still view
malpractice litigation as a way to regulate and
control "a profession that is unaccustomed to

external policing". ' In fact, so me lawyers
perceive them selve as "champions of patient
afety" who are fighting battles with the
healthcare system on behalf of patients. '
This complex and imperfect system of
malpractice lawsuits has created a significant gap
between the views of medical professionals and
the views of their patients. While physicians
believe they are being unfairly targeted, their
patient hold the view that legal action is an
effective way of policing their doctors. ' Legal
questions that proceed to court inherently
become adversarial, with lawyer for each side
hired to defend the intere ts of those who have
retained their ervice . The inherent adversarial
nature of these legal contests cannot help but
obscure the common goal of physicians and
patients of improving patient ' health , which in
tum may reinforce mi conceptions and di stru t
and damage the doctor-patient relation ship that is
o important to effective medical care. The
United States ha 70 percent of the world' s
lawyers, and five percent of the world 's
population -- a supply of one lawyer for every
265 people? Social observers who note the way
Canada is becoming more similar to the United
States may see a cautionary tale with respect to
increased litigiousness in Canada.
In order to fully appreciate the extent and
complexity of medical malpractice litigation it is
important to consider the definition of medical
malpractice as well as the laws and procedures
followed in Canada. Moreover, trend
in
malpractice lawsuits for practicing physicians in
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the fi eld of Cardiology will be used a a ca e
study.

What is Medical Malpractice?
Although di cuss ions in volving malpractice
li tigati on
can
in vo lve
complex
legal
techni calities, there is a fairly inclusive and
wide ly agreed upon defini tion for medi cal
malpractice. M uch of th e d i crepancy in the
views of the d iffe rent parties to the e di pu tes
can then be understood as d isagree men t over
which events and occ urre nce fa ll under this
broad defin ition , and whi ch do no t.
Medical malpractice can be defined as an
act or an omission by a health care prov ider that
deviates fro m accepted standard of prac tice in
the medi cal fie ld and whi ch cau es injury or
harm to the patient. 3 M alprac ti ce can result fro m
negli gence,
professional
mi conduct,
carele ne , and/or failure to u e adequate levels
skill or diligence while cari ng for a patient. To
determjne and e tabli sh an accepted standard of
care, comparison is made to typical care offered
by ph ysicians in the community; in other wo rds,
compari son i made to standard applied within
the same geographical area.
Another matter th at fa ll s under the
category of medical malpractice is failure to get
a pati ent' info nned consent. A ph ysician mu st
fully in fo nn the pati ent about th e nature of the
diag no ed condi tion, the range of treatment
o ptions, and the know n major ri k ? of each. It
i interesti ng to note that when a doctor inform
a pati ent of the risks associated with a procedure
or a treatment, they don' t have to ex pl ain all the
pos ibl e ri sk . T hey are onl y respon ibl e for
ex pl ainin g those ri sks that a ' rea onabl e ' pati ent
wo uld want to know before makin g the ir
decis ion. In addi tion, even if the practiti oner
does not prov ide the ir pati ent with all the
inform ati on, the phy ic ian will not be li able if a
' reaso nable' person in the ir positi on wo uld have
agreed to the pro posed treatment or procedure
anyway, even if the phys ic ian had g iven them all
3
the informati on.
Thi ex tensive and broad de finiti on of
medical malprac tice leaves many issue open to
the interpretati on o f judges, juries, and lawyers.
Thi s leaves much roo m fo r inequ ality and
incons istency in judgments and compensati on
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for patients. Ph ysici ans are taught to understand
the considerable amount of uncertainty that
accompanies
diagnosis,
and
appropriate
treatment but members of the public may not
'
fully appreciate
that medicine is not an exact
cience and that doctors are not able to make the
correct 'diagnosis every time. Doctors may order
the appro pri ate te ts and procedures and follow
the standard of care in a given location and still
make either no diag nosis or, in some cases, the
wro ng diagnosis. If a phy ician doe all that i in
the ir power to help the patient, and still
misdiagnoses a pati ent, are they liable, and is thi s
cons idered malpractice? Depending on who
interprets the law
and the definitio n of
malprac tice, a ph y ic ian may in some cases be
till taken to court even after following the
appro pri ate stand ards of care.
It i imperfec tions such as the one
menti oned above, which are a cause of concern
fo r ph ysic ians and th e health care indu stry. It is
very important to keep in mind that because of
medi cal
uncertainty,
doctors
cannot
be
guarantors of the ervice which they render with
one hundred percent certainty. A physician is,
however, legall y required to have the necessary
know ledge and ex peri ence to perform the
ervice in que ti on. Further, doctor mu t
exercise the ki ll and care that other in the
co mmunity u e when dealing w ith imilar
itu ati ons.

The story in Canada
T he medical malprac ti ce liti gati on c risi has not
reac hed th e everity seen in the United State .4
The compl ex ity of the itu ati on there will be
di cu ses later in the artic le. In th e meantime it is
important to appreciate that takin bo- leo-al
action
b
with re pect to medi cal ma lpractice cases is
much more difficult in Canada whe n compared
to the United State and even the United
4
Kingdom. In fac t, "Canadian judges tend both
to be more reluctant to find breach of medical
standard of care, and to require mo re exactin oproof of causati on". 4
o
.. In . addition, defence of prac ti cing
ph ys1c tan ~~ Canada is killfully managed and
generously fm anced by the nonprofit Canadi an
Medical Protective Associati on (CMPA), a
mutu al defence a sociation o f phys icians. 5 The

CMPA, founded in 1901, is funded and operated
on a not-for-profit bas i by ph ysicians. The
organization has more th an 71 ,000 member
co mprisin g about 95 per cent of the doctors
licen ed to practise in Canada. 5 The CMPA will
do all that is in its power and will in ves t heavily
in defending any ph y ician action th at is in any
way defen ible. The organization's main aim i
to prevent the setting of medical malpractice
precedents th at could cause irrever ible damage
to the profess ional reputation of the medical
profession as well as long term financial
4
burdens. The CMPA's contract with their
member physicians is for unlimited coverage,
with few exceptions. Some of the exclusions
include cases involving ethical violati ons by a
physician, uch a sex ual mi conduct; in such
circumstances the CMP A will not cover the
physician but will pro vide them with defence
4
counsel and advice.
In term of medical malpractice litigation
in Canada, there are a number of trends that need
to be di scussed. These trends include the rate at
which legal action is taken against practicin g
physicians, and the cost of malpractice insurance
in the country.
On the positive side, the CMPA has made
it clear that legal actions against ph ysici ans have
declined over the past decade fro m about 26 per
1000 members in 1996 to 13 per 1000 members
in 2006.6 In other words, practicing Canadian
ph ysicians today are half as likely to be involved
in medical malpractice lawsuits than they were
10 years ago. This maybe interpreted as resultin g
from a growin g emphasis on pati ent safety and
ri sk management by doctors, or it can be seen to
have resulted from a more extreme approach of
the CMPA in the pa t decade to preserve the
profes ional reputation of medicine.
However, while the rate of liti gation
against Canadian doctors has been declining,
there are other trends that are quite troubling. For
ha
instance, the cost of medical liability
increased signi ficantly over the past decade, with
annual damages and legal and ex pert
administration costs rising from about $ 170
million in 1997 to more than $400 million by
2006. The median damage cost increa ed from
about $30,000 in 1996 to nearly $ 100,000 in
2006.6

In addition, the CMPA has identified a
trend of "increasin g intru sions on a physician'
ri ght to due proce s in the name of patient
safety".6 However, these claims are subj ective,
may be bi ased , and are diffic ult to verify witho ut
the in volvement of an independent entity that
does not have special interest in the iss ue of
med ical malpractice litigation and their
outcome .
Another tro ubling trend, which does not
seem to be affected by the decline in legal
action again t physician , i the rising cost of
malpracti ce insurance in Canada. Over the past
decade there has been a steep increase in the cost
of malpractice insurance in the co un try that is
begin nin g to have a ignificant effect on
practici ng ph ysicians. It has been estimated that
as of 2001 , average insurance rates in On tario
had climbed by nearly 45 %, while rates in
M anitoba, Saskatchewan, and Alberta had had a
7
more modest increase of 11 % by the same year.
And , since Canada in general, and Ontario in
particular, ha a worriso me physician shortage,
the significant increase in malpractice insurance
fees in so me provinces may put these
jurisdi cti ons at a disadvantage when recruiting
7
and retaining doctors. Although most specialti es
are being affected by the insurance fee hikes,
some specialtie
such as
Orthopaedics,
Neuros urgery, and Obstetrics have been more
significantly influenced. 7
These figure clearl y upport the view
th at there ha been an increase in malpractice
insurance fees in Canada and the awards in
malpractice court decision . However, contrary
to popular belief and the selecti ve media report
describin g the high-profile, high-cost cases, the
perception th at Canadi an doctors are maki ng
more mi takes and that they are more likely to
get ued than in the pas t is false according to
research conducted by the Canadi an Health
Services Research Foundation (CHSRF).8 In
reality, the number of medical malpractice
lawsuits filed in Canada peaked at 1,4 15 in 1996,
and has been on the decline since. 8 Furthermore,
an increa in g percentage of lawsui ts that went to
trial concluded with j udgments in favour of the
physicians, fro m 73% in 1994 to 82% in 2004. 8
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Malpractice in Cardiology
After considerin g the general concerns with
medical malpractice litigation in Canada, we will
now go on with a bri ef overview o f issues with
medical malpractice in the fi eld of Cardiology.
E ven though there is a plethora of informati on
pertaining to medical malprac tice liti gati on in
general, it wa very di fficult to find Canadi an
data pertaining pecifi cally to the fi eld of
Cardio logy. However, the A merican College of
C ardio logy prov ides so me in fo rmation th at can
be used to get a general idea about what is
happening within thi s field of medicine in North
America.
Ju st as in other medi cal spec ialti es,
medical malpractice liti gati on has been a key
area of co ncern for Cardi o logists. Costs of
medical malprac tice insurance have been
increa in g rapidly, and the rates for doc tors in
Cardi ology are co nsistent with those in oth er
9
high-ri k specialti es. This has had a significant
effect on the li velihood of such ph y ic ian , and
has even fo rced orne of them to leave th eir
practice. Thi trend has been een in the United
State , but presumably th e situati on is similar yet
pro bably not as ex treme here in Canada. As for
th e causes behind thi increase in premiums, th ey
are pre umably simil ar to other pecialti e in that
they include "fri volous laws uit and exaggerated
monetary award ", in additi on to the exodu s o f
o rne major insurance carri ers from the market. 9

Future Outlook
At thi s point in time, the future outl ook for
ph ys icians is bl eak at be t. Medi cal malprac ti ce
ins urance pre mium s are still on the ri e, and
monetary award in the cases where the rulin g i
in favo ur o f the patient are rapidl y increas in g.
The only bri ght side to all o f this is the fact th at
there has been a decrease in the rates at whi ch
physic ians are being sued. Howeve r, th at has not
been e nough to slow dow n th e trend of
inc reasin g in surance fees .
The questi on that co me to mind at this
point is wh o reall y is respons ible for the c ri si ?
And if more th an one party is res ponsible, then
will any of the m stand up and do so methin g
about it? Sh ould the government attempt to
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reform the laws to better protect both doctors and
patients? What is the evidence that patient safety
is actually improved by the pre ent system?
Should the medical profession cease to be
regulated by the physici ans themselves? Should
ph ysicians accept a greater role by the
government in policin g the medical profession ,
in exchange fo r legal protecti on against frivolou s
and unreasonable legal actions? What if anything
can be learned from other countries? These are
all complex questions, with no simple an wers.
Hopefull y, by introducing the key organizations
and parties in vo lved and the important trends
and indicator to watch, this paper will help the
reader be more informed as thi s complex debate
unfo ld .
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Profiles
Dr. Richard J. Novick on Guns, Germs and Steel- Perspectives from a CardioThoracic and Transplant Surgeon
Alysia Zhou, Medicine 20IO
Reviewed by Dr. Richard Novick
I was a medical tudent on surgery at the Royal Vic [in Montreal] o ne ni ght when I got a stat page to go dow n to
emerg. In emerg there was a policeman who had bee n s hot down on Pee l St. at the j ewe lry store where he ca me across
a robbery. The g uy wa lyi ng on the stretcher, hi eyes ro ll ed back, hi blood pressure wa 50, there was blood
spurting o ut from his chest - it was a to tal ni gh tmare situation and I was the o nl y one there. So I said, " Get the s urg ical
chi ef res ident; get the atte nding." I put an IV in thi s guy o I fe lt pro ud about that; th ey intubated him . The Chief
re ide nt ca me a minute later, got o n the phone and sa id , "Get me an OR."
We went up the e levator and in the meantime the police man arrested o we started CPR. As we e ntered the
OR, I wa sitting with my knees on the bed and pumping o n hi s chest while blood was pouri ng o ut a ll over the pl ace. I
was so tachycardic my pulse was throbbing in my ears. Paul (the C hi ef resident) opened the chest and the guy was
sti ll fibrillating so he ope ned the pericardium and massaged and zapped him internall y. He came back but hi s BP wa
just 50 and there wa black blood spurting from hi s ri ght ventric le. Paul aid, "G ive me a 2-0"; he took the 2-0
prol ene, put it into the RV and turned to me: " Novick take thi s driver." I wa ho ldin g thi s driver and shaking like a leaf
and he said, "When I put thi s need le through, you grab the tip of the need le and you bring it thro ug h." So he put the
need le through, I grabbed it and the policeman fibrillated agai n; we defibrillated and blood was still pouring out. The
second need le came through , I grabbed it, Paul tied a knot and the bleeding stopped. Thi s wa a yo un g man who
didn ' t have coro nary disease and all of a sudde n the BP was 78 , 80 ... So we stood there fo r about an hour irri gatin g
and closing the policeman. after which we brought him to the unit. Of course he had every comp licatio n under the s un ;
hi s kidneys failed and he needed dialysis but six weeks later he walked out of the ho -pital in excell ent shape. That was
one of my first nights o n call in surgery and I wa there for hi s whole hospital stay .

Not short of an episode one would see on the
television series E.R. , this was, however, a reallife pivotal experience for a young third year
medical student and now Chief and Chair of
Cardiac Surgery, Dr. Richard J. Novick.
With a 42-page curriculum vitae
detailing over 125 publications, numerous
appointments, grants and awards, as well a
knowing six languages, Dr. Novick is truly a
renaissance man . Born and raised in Montreal,
Quebec, hi s talents were fostered by a liberal
arts philosophy instilled in him by his parents of
the importance of having a broad education. He
grew up in a "medical hou ehold" and hi s father
still practices otolaryngology in Montreal at age
84. True to this broad education of philosophy,
Dr. Novick took a path less traveled and
pursued a degree in Philosophy at Brandeis
University in Boston , with a minor in biology.
His honors thesis wa an analysis of the original
works of Jean-Paul Sartre's theory of
existentialism.

Towards the end of the 3rd year of hi s
undergraduate studies, Dr. Novick knew that
deci sions had to be made about what to pursue
after his Bachelor's degree. To keep his options
open, Dr. Novick wrote the MCAT, LSAT and
GMAT exams. After much personal reflection
and di cus ion with his family , Dr. Novick
decided medicine was hi s true callin g.
Ironically, Dr. Novick started medical school at
McGill Univer ity in the fall of 1976 in the
same class as hi younger brother of 15 month ,
who pursued a pre-medical education at McGill
and was focused on medicine at a young age:

I had the bare minimum of sciences, so the first
few months of med school were torture for me:
pretty much the only reason I survived was: 1) I
worked very hard, and 2) my brother helped m.e.
He had done anatomy, histology, and
physiology the year before. When I looked under
the microscope, I had no idea -.,vhat I was
looking at. I had never looked under a
microscope before in my life; even in biology in
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College it was all conceptual learning. By the
middle of first year, however, everyone was ort
of the sam.e in terms of their knowledge base so
those of us from a non-science background
caught up pretty quickly.

It was almost as if it was just a little scrape. So I
1
decided in the beginning of 4 h year that I
wanted to be a surgeon. For m.e, it was
undifferentiated initially, and then I only
thought of cardiac surge1y later.

When asked on how he decided during medical
chool that surgery was his pass ion, it often
came down to the clinical ex perience , the
teachers and mentors he encountered throu ghout
hi s medical educati on, and keepin g an o pen
mind throughout hi
clerk hip year. For
in tance, Dr. Nov ick came into medicin e
con ide rin g psychi atry to be an area of intere t
because of hi undergradu ate and volunteer
ex perience related to psychology, a we ll as
having a mentor in the fie ld.
Durin g medical choo l, Dr. Nov ick
excelled in variou fi eld of medi cine, inc luding
winning the Franci William Pri ze for the
hi ghe t achi evement in Intern al Medicine. Hi s
clerkship year al o bro ught him into contact
with Dr. L. D . Macl ean, Chi ef of Surgery at
McGill, who became Dr. Novick's mentor
throu gho ut hi urgery ro tati on. Thi , co mbined
with e minal event that occ urred during hi
urgery rotation at the Royal Vi ctori a Hospital,
helped Dr. Nov ick narrow hi area of interest
and " o after that ex peri ence psychi atry wa a
negati ve and surgery, although intense, wa
pretty pos iti ve."
With electi ve time and the res idency
matc h loo min g, Dr. Nov ick requ ested a cardi ac
surgery e lecti ve and wa launched into another
life-changin g ex peri ence:

Dr. Nov ick decided to apply to the US match
becau e he wanted a broad and intense
ex perience. He therefore applied to numerous
American in tituti on , "including all the major
kni fe and gun clubs." He subsequently matched
to Bellev ue Ho pital and the New York
U ni versity M edical Center.
Moving to New York and embarking on
what wa to be an "earth -shattering experience,"
Dr. Novick wa thru st into the full intensity of
hi urgical intern hip from day one. In addition
to the re pon ibiliti e o f being a newly minted
MD, the ' 80 pro ved to be a high tre period
for all healthcare worker a AIDS and HIV
were ju t co mjng into the foray o f medical
knowledge.

I had the good fo rtune to spend a month as a
medical student on cardiac surgery. It was Dr.
Tony Dobe/l who was the second surgeon to
mentor me. He was Head of Ca rdiac Surgery at
the time and a world-renowned pediatric
surgeon. He also did a f air number of adult
cases and he took m.e under his wing. Th e most
amazing thing with Dr. Dobell was that no
m.atter how bad things got he would always stay
calm. For example, there could be a hole in the
aorta with blood flying past his head and he
would just put his fin ger on it and ·ay, "A lit1le
bit of mild oozing here- maybe I'll take a 4-0 "
and put the 4-0 through and solve the problem.
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Back then, the crime rate were dramatically
higher in New York City than they are now. It
was also a cra::_y time becau e people were
starting to appea r with big lymph nodes and
pnewnocysti pneumonia. AIDS wasn 't officially
labeled until 19 4 o there were all these sick
people coming to emerg coughing and
hypoxemic and a week later they were dead ... It
was a high ri k time across the board. There
was no universal precaution and f rankly, we
were lucky I to not have contra ted disease
our elve /.
I was on the I rauma service my first two months
and on call one in two. During m • f ir t night,
things got a bit quiet at midnight o I asked the
ward nurse. " Where i the on call room ? "
She started laughing and replied, "There's no
on call room here ... You 're never going to get to
bed. ··
" Well it 's quiet now and I want to go to bed " 1
responded.
The beeper then rang and reported, '' Dr. Novick
there's 23 patients f or you to asses in emerg. "
There was no sleep; it wa total brutality .... You
sta r~ed pre- rounds at 4:30am. the Chief
Restdent came at 5:30am and expected you to
take him. around ... There were patients on 5 or 6

different wards and severaL different ICUs and
you had to draw the blood and measure cardiac
outputs yourself, as weLL as know every patient's
lab value.
On your night off, you'd get out at 10 or 11pm,
go to your apartment, have a Little bit of supper,
crash for 3 hours and then the whole cycLe
would reswne ... For exampLe, there were two
days where I didn't eat anything. You 'd see a
cart of muffins being pushed down the haLLway
after rounds and Like a rabid anim.al, you would
grab a donut because you hadn't eaten in 36
hours. There was no one Looking out for you.
Drug trafficking and gang violence in the area
would guarantee Dr. Novick and the hospital
staff that on every Friday shift at 2:30 or 3am,
they would have "3 or 4 people shot up very
reliably" with some coming to emergency DOA.
The pecking order of the resident would dictate
who did what in case of multiple gunshot
victims coming into the hospital:

There were a couple of times where we had
three gunshot wounds staggered. So the first one
I would resuscitate, put the !Vs in, intubate and
get him. up to the OR and the R5 would be
opening him. Another one would come in and
the R3 would open him up so both ORs were in
progress. And then a new gunshot victim would
come in and then I had to do the resuscitation,
sometimes a left thoracotomy to put a cLamp on
the descending aorta if it was a major
abdominal exsanguination. That would fairly
reliably get the patient back but then you'd have
to get him into the OR with an open chest and
blood is dripping down the haLLways as you
wheeled him to the OR. You've then got to prep,
drape, open the belly, and by then the R5 would
come over because som.eone else would be
cLosing the first gunshot wound that came in.
It was pretty catacLysmic. I did two months of
training in trauma, and then I had rotations in
neurosurge1y, cardiac and plastic surgery at
NYU. I did orthopedics as well at Bellevue. It
was a real rotating surgical internship and I
saw everything.
Most of the trauma populations were pretty
unsavory people; they didn 't have a healthy

lifestyLe so I had concerns about getting serious
disease myself. And then also the sheer intensity
of it: with 160 hours in a week, I was in the
hospital for 125 to 130 of those hours. My
health held up but there were a coupLe of people
in our group who didn't fare so well. We were
16 initiaLLy, but one guy took his own life and
couldn 't handLe it. Another colleague of mine,
and I was actuaLLy very Lucky, wanted to switch
caLL with me so we switched on short notice. He
left the hospital and got stabbed 14 times
literally m.inutes after leaving and barely
survived; I had just been talking to him severaL
minutes previously. So I had severa L concerns
about my personal safety.
As Dr. Novick's intern hip was nearing an end,
an "awkward week, ju t like a pivotal week
when I decided to go to medical chool" helped
him in deciding where to pursue hi residency
training.

I had, for severaL months, doubts that I really
wanted to stay in New York and I had just heard
that there was an opening at the Royal Vic in
Montreal. The Chief of Surgery. Dr. Maclean,
had spoken to m.y dad, who still works there,
asked how I was doing and mentioned that they
had an opening for a second year surgical
resident [equivalent to a PGY3 position]
because of my experience in New York. I was by
then engaged and my fiance (and subsequent
wife) Terri was working in Montreal.
In deciding to return to Canada, Dr. Novick
turned down the offer of a Chief Resident
position at Bellevue. During hi s re idency at
McGill, Dr. Novick found time to also complete
his Masters of Science degree in Experimental
Surgery within cardiac urgery, ' and it was in
that year that I decided ultimately I was
intere ted in cardiac surgery." In fact, Dr.
Novick started in the cardiac surgery program
without even having a formal acceptance letter:

I remember very well Dr. Dobell, one of my
mentors, walking dmvn to the Lab toward the
end of my research year and said "Richard
you've been doing great work, you've published
a couple of papers already, and you 're going to
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be writing your Master's. Do you want to be a
cardiac surgery resident in our program ?"
I had been thinking about it for a few months
and replied, " Well let me speak with my wife."
Dr. Dobell replied, " Well if you want it it 's
yours."
"But don 't you have a selection committee ?
Don 't I have to fill out an application ? Don 't I
have to interview?" I asked.
" Well here, shake my hand'' he responded. So I
decided to go into cardiac surgery and in fact I
never had any I'Vritten acceptance letter. But
back then it was a different time. He gave tne his
word, he shook my hand and told me I was in
the program.
Within a period of 4 years, Dr. Novick had
written 12 fellow hip exam s which included
Quebec, Canadian and American board exam
in General Surgery, as well as Cardiac and
Thoracic Surgery. It was al o a time of rapid
change in the field of surgery with
tran splantation starting to be offered a a
treatment for conditions that previously proved
fatal :

Those were early days of transplantation but at
the Royal Vic there was a transplant progrmn
and a very energetic transplant surgeon, Dr.
Albert Guerraty ... We would do a transplant and
I always peJformed the donor run to bring the
heart back. Usually at the beginning Albert
would sew it in; sometimes I would at the end.
During the pivotal first f ew hours after
transplant, we camped out with the patient and
we took care of them 2417 f or 3 or 4 days. I
would do two of the days, Albert would do one.
It was a cataclysmic experience. We did 9 or 10
transplants during the time I was at the Royal
Vic and all survived.
To further develop hi s clinical and research
interest in transplant urgery, Dr. Novick, with
the help of hi s mentor Dr. Dobell, entered the
tran splant fellowship program at Stanford
University. Following hi s fellowship , Dr.
Novick was offered a co nsultant position at th e
Montreal General (a McGill-affiliated Hospital),
but wanted to ee what other opportuniti e were
availabl e.
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I sent a bunch of letters around to every centre
in Canada. Dr. McKenzie from London
responded and set me up for an interview. My
youngest sister was a law student at Western so
I stayed in her Cherryhill apartment. My
interviews were arranged for the Monday
morning with Dr. McKenzie, whom I met once
at a meeting, as well as Dr. John Duff, who was
Chair of Surgery. So I was at my sister's place
and we went out .for supper on Sunday night
when she told me, "I don 't feel so well."
" What's the st01y, do you have food
poisoning?"
"No, no. I have pains. " She explained.
I examined her and she had rebound in her right
lower quadrant.. .So I scooped 1ny younger
sister, who could barely stand up straight, into
my rental car and brought her up to emerg at
UH. The general surge1y resident cam.e and
sure enough she had appendicitis and Dr. Duff
was on call. I was supposed to have an
interview with Dr. Duff at 7am on Monday
morning and here we were past m.idnight on
Sunday.
All of a udden I wa n 't a surgeon anymore, but
rather a family member in the waiting room.. So
my sister got her appendix out and Dr. Duff
came to m.e at 2am and said, " We found an
inflamed appendix, eve rything 's good. " So I
asked him. " Would you pref er to have the
interview now? ..
"No come back at seven. "
I remember going back to her apartment and
having a f ew hour of sleep before the interview.
I was basically overwhelmed by what was
available [in London] . First of all, I recognized
that Dr. McKenzie would be an exceptional
mentor, which he has been .for the past 19 years.
The fo cus back then was transplantation - nwre
transplants were being done here than in
Montreal and it was all under one roof Even
though I didn 't know a soul in London except
for the people I had just met, I decided to com.e
here and have never regretted that decision.
When a ked about what factors influenced him
to choose to become an academic cardiac
urgeon:

Some people wish to be big volume cutters and
they're better suited for community practice.
There are others who place primacy on the
academic m.ission. I also did a Graduate
Certificate in Clinical Epidem.iology and
Biostatistics and have always cultivated a wellrounded practice. I' ve done an intennediate
volume of cardiac surgety cases but ha ve
always had grants supporting laboratory or
clinical research.
The major difference benveen community and
academic practice is that with the latter, 1) you
have to be a teacher to medical students and
residents. You spend a lot of time with the
residents; they get to know us and we get to
know them very well. 2) You have to make a
valuable academic contribution. That makes for
a very busy life professionally to the point where
your career can be all-consuming.
So balance, i it even pos ible?

If anyone in my position, for instance, with
major academic, administrative, and clinical
commitments tells you they've got a wellbalanced life, they're not being fully truthful.
But you learn how to cope ·with innumerable
demands and do the best you can.
There are several ways to accomplish that and
one is by delegating. My administrative
assistant knows the way I approach issues, and
handles administrative tasks in a proactive
manner. In addition, my secretary has been
employed by me since the onset of my practice
in 1988 and runs a very efficient office.
Furthennore, the residents and fellows work
very hard. Academically, we have a clinical
research associate who is very conunitted and
knowledgeable.

Above and beyond the adm.inistrative, teaching,
research and clinical work, many of us, myself
included, have a larger responsibility to the
field as a whole. I was the Associate Editor for
the Annals of Thoracic Surgery for 10 years,
which is one of the tvvo major publications in
our field. Presently, I'm on the Royal College
Cardiac Surgery exam. committee.
You need to ha ve a supportive family, and that's
not only a supportive spouse but also kids who
understand. You need to have a lot of energy
and be willing to wake up very early and be a
rigorously efficient as you can with your tim.e.
Even with highly capable people to delegate
work to, it's still a scramble on a daily basis
and you really don't have much free time.
Complementing Dr. Novick' role as a leader,
teacher, mentor and innovator i a clear
recognition of teamwork and the contribution
of others in helping the divi sion to succeed :

There's only so m.uch one individual can do so
it's basically the team; cardiac surgery is the
commensurate team sport.
I'm very proud of our team. at all levels. We
have state-of-the-art individuals including our
bedside nurses, perfusionists, our residents who
work vel)' hard, and of course my fellow faculty
members, each one of whom has eve f)' rea on to
be very proud of what they 've accomplished in
their careers.
Evetyone has m.ade a major contribution to this
enterprise. For some the focus is clinical and
technical excellence in surgery, for other it 's
research, andfor other it 's teaching. Everyone
has made a wondeJful contribution, ·which has
made my job much easier. I'm very proud of the
team.
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Thinking on Your Feet
Atrial Septal Defects in Adults
Todd Greenspoon, Medicine 2010 and Aiman Alak, Medicine 2011
Reviewed by Dr. Keith Finnie
Atri al septa l defects (AS D ) are abn orma l co mmunica ti ons between the left and right atria all o wing mixin g o f the
bl ood between the e two compartme nts. ASD are the econd mo t commo n conge njtal lesions in adults.
Embryologicall y, the septum betwee n the atri a i made of eptum primum covering the ostium pri mum orfice, and the
eptu m ec und um covering the ostium sec und um orfi ce. In 70 % of the popu latio n, these epta fu e. A pate nt fo rame n
ovale ex i ts if the space is covered but the epta are not fu ed . An AS D exists whe n an open communicati o n exists
between atri a. A large AS D can ca u e ex tra blood to acc umul ate in the ri ght atrium and ri ght ve ntri c le . Eventuall y, the
hu nted fl ow causes ri ght ide di latati on, main pulmo nary artery enlarge ment, and increase in pulmo nary vascul ature .
Most ASD are asy mptomati c in infancy a nd pre ent upon routi ne physical exa mi nati on. T he time it ta kes fo r
symptom uc h a heart failure, genera lized edema, exerc i e in to lerance or dyspnea is in ver e ly re lated to the ize of
the ASD. O n phy ical exami nation, the most co mmo n fi ndi ngs are a precord ia l bul ge, abnormal murmur , and
ex traneo u heart so unds. T he most u e fultest in the identi fi ca ti on and q uanti fi catio n o f the AS D i an echocardi ogram
(tran thorac ic or tran esophageal, with or witho ut Doppl er); ho wever, other in ve ti gati on includ ing ECG a nd chest
radi ography may be uti li zed. Mechanical c losure i ind icated fo r pati e nt that develop sympto ms or have a large
degree o f le ft-to-rig ht hun t.
Hi tori ca ll y, surgical c los ure ha been the mainstrea m treatme nt, but recentl y
percutaneou device have come to the fore front in the repair of ostium sec undum AS Ds because o f the ir excellent
outcome and decrea ed peri operati ve morbid ity. T he tra nscatheter approach ha all owed e lderly patient and tho e
wi th co- morbidities to undergo cl os ure o f their AS Ds and thri ve afterward .

Case
A 19 year old tudent presented with an
incidentally noted irregular heart beat. Pati ent
worked out regul arly, but hi s aero bic endurance
wa not th at great. He was not a smoker. He had
no fa mily hi tory of congenital heart di sease. He
did not take any medications, and had no
all ergies. He had no pro blems w ith palpitati ons,
li ght-headedne s, or yncope. He had no medical
hi story. He weighed 76 kg. Hi blood press ure
was 110170 mmHg. Hi s heart rale wa 62 beats
per minute and reg ular. His seco nd heart ound
was widely split and fi xed. Hi s murmur was
described as a midsy tolic pulmonary ejecti on
murmur.
Che t x-ray revealed cardi omega ly du e to
ri ght ventri c le enlargement. Echocardi ograph y
revealed th at hi s ri ght atrium and ri ght ventri c le
were moderately dil ated. Hi s ri ght ventricle had
mildly reduced systo li c fun cti on, and co lor flow
Doppler
sugge ted
left-to- ri ght
shunting.
Transesophageal ECG found a dilated ri ght
atrium and ri ght ventricle, moderate ri ght
ventricle global hypokinesis, and a 1 em o tium
secundum atri al septal defect with left-to-ri ght
shunting.
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Patient underwent a perc utaneou device closure.
Arrangements were made fo r foll ow-up in 2
months.

Introduction
Atrial eptal defects (ASDs) are the second most
co mmon congenital lesio n in adults. A patent
fo ramen ovale (PFO ) exi ts in 30-40 % of the
normal adult po pul ation.' In an ASD, a defect in
the in te ratrial eptum of the heart allow mi xing
of the blood in the ri ght and left sides of the
heart. The ex tent of he modyna mic and clinical
signi ficance depends on the ex tent of shunting.
Embryology: The moth er's placenta provides
ox ygen for the foetus, o bl ood can bypa s the
2
lungs. In earl y weeks of ge tatio n, an orfice,
o tium primum , exi ts between the atri a.
Beginnin g in the 5th week, the septum prim um
be~in s clos ing th_e orfice. Within thi s septum, an
orftce call ed ostium secundum fo rms, which in
tum beco mes clo ed by the eptum ecundum.
The _septum ecundum does not co mpl ete ly seal,
leavmg th e f~ram en ovale. The septum primum
forms a fl exible fl op on the left side o f the
foramen ovale. However, since the right atri al
pressure i higher th an the left side, the fl exible

flap is pushed aside holding the foramen ovale
open. At birth, expansion of the lungs and
increase in systemic vasculature resistance
reverses the atrial pressure gradient; the flap is
held down and the interatrial hunt ceases. In
approximately 70% of the population, the septa
fuse after birth. A " probe patent" or " patent"
foramen ovale (PFO) exists if the space is
covered but the septa are not fused. A reversal of
the interatrial pressure gradient or an intercardiac
catheter can open the PFO. An ASD exists when
an open communication exi ts between the atria.

Pathophysiology: Many types of ASD exist, but
the pathophysiology is very similar? Normally,
the left side of the heart has a higher pressure
than the right side. A large ASD can cau e extra
blood to accumulate in the right atrium and right
ventricle. Pulmonary to systemic flow ratio can
be as high as 8:1, while some patients can have a
5:1 ratio but be asymptomatic. Eventually, the
shunted flow causes right size dilatation , main
pulmonary artery dilation , and increase in
pulmonary vasculature. Untreated, the inc rea es
the size of the right ide of the heart can lead to
heart failure. Any increase in the pressure in the
left ventricle, such as by hypertension and
coronary artery disease, worsens the left-to-right
shunt. Overload of the right side of the heart, in
tum, overloads the pulmonary vasculature, which
leads to pulmonary hypertension. The pulmonary
hypertension further overloads the right
ventricle, called afterload, and results in the right
ventricle to generate higher pressures to
overcome
the
pulmonary
hypertension.
Potentially, the right ventricle fails or the
pressure in the right side of the heart becomes
higher than the left side. As the normal pressure
differential between the right and left ides of the
heart decreases, the
hunting decreases.
Eisenmenger' s syndrome describes the situation
where severe fixed pulmonary hypertension
caused by the shunt leads to elimination of the
left to right shunt and bi-directional or right to
left shunting leading to arterial desaturation and
cyanOSIS.
Types of ASDs: Many types of ASDs exist?
Primum ASDs are typically associated with
ventricular septal defects and/or A V valve
malformations. Poor growth of the secundum

eptum or exce sive absorption of the primum
septum is called secundum type ASD. Thi s type
accounts for 70% of all ASDs, and i more
common in female . It can be as ociated with
other ASDs. Some patient have a family history
of this defect. An abnormality in the insertion of
the superior or inferior vena cava can form an
interatrial communication outside the fo sa
ovalis. This defect is called sinu s venosu ASD.
When a part of the wall between the coronary
sinus and left atrium is absent, the defect is
called coronary inu ASD. A PFO is not a real
ASD. It can be detected in 25 to 40% of normal
adult hearts.3 PFO may be a famili al trait.

Management
History and Physical Examination
The vast majority of small ASDs are
asymptomatic in infancy and childhood, and they
are found secondary to hearing an incidental
murmur upon auscultation of the chest. The
minority of newborn s with small ASDs may
present with mild cyanosis with right to left
4
shunting across the ASD. Typically small ASDs
are not associated with a significant shunt and o
may not be associated with a mUimur or any
abnormal findings . Infants and children with
larger ASDs may pre ent with hea11 failure ,
failure to thrive, or recurrent respiratory tract
infections. 5
Patients with moderately ized
ASD , if not corrected, will develop symptoms
such as heart failure , hepatomegaly, generalized
edema, atrial atTthymias, exerci e intolerance, or
dyspnea later in life (usually before age 40) as
the degree of left to right hunting increa es with
age. 6
There are numerous physical findings
associated with ASD . Children with an ASD
may be small for their age, even in the absence
of complications uch as heart failure . Upon
palpation of the precordium there may be a
precordial bulge, a right ventricular heave , or a
palpable pulmonary artery at the second left
interspace. During au sculatation of the heart
commonly a widely spaced second left hear~
sound is present hypothesized to stem from the
increase in pulmonary arterial flow and delayed
closure of the pulmonic valve.7 This, however, is
u ually absent in newborn because of a minimal
left to right shunt. If the ASD is associated with
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pulmonary
hypertension
the
pulmonary
component of the second heart sound i louder
than u ual. The u uall y split fir t heart sound
mi ght be even more pronounced in patients with
ASDs because of increa ed blood flow needed to
occur across the valve.
A variety of murmur may be associated
with ASD primaril y or econdary to pulmonary
hyperten ion.7 It is important to reali ze that the
blood flow aero s the ASD contains in ufficient
turbul ence to be au cultated. The prim ary
murmur incl ude: a mid y tolic pulmonary
ejection mu rmur becau e of increa ed fl ow
thoro ugh the pulmonic valve, a mi d diastoli c
mu rm ur econdary to increased flow across the
tricu pid valve, a di asto li c murmur consi tent
wi th pulmonary regurgitation becau ·e of
pulmonary trunk dilatati on, and a y toli c
ejecti on murmur be t heard over the lun g
con i tent with increa ed flow th ro ugh the
smaller pulmonary arteri es. Additi onall y, with
pulmonary hypertension patient with ASDs may
have additional murmur and ex traneous heart
ounds.
Other Investigations: In the evalu ati on of a
patient with an ASD the most utili zed te t are
the echocardi ogram, the electrocardi ograph , and
the chest x-ray. Echocardi ograph y is the mo t
useful te t fo r the di agnosis of ASD.
Tran thorac ic echocardi ograph y is u uall y
di agno tic;
however,
transe ophageal
echocardiograph y can prov ide additi onal
inform ati on regarding the ize of the defect and
the other a sociated co ngenital anomali e . The
vo lume of blood shunted, the shunt ratios, a
we ll as pulmonary artery press ure can be
mea ured with Doppler fl ow echocardi ograph y.
Treatment: The two main indicati ons for surgical
or percutaneou clo ure of the ASD are the
development of sy mptom. or a large left to ri ght
shunt. 4·8 The Ameri can Heart A ociati on
reco mmends closure when the Qp/Qs i greater
th an 1.5:19 , while the Canadi an Cardiac Soc iety
recommends closure when the Qp/Q is greater
than 2:1 , or greater th an 1.5:1 in addition to
. Ie pu l monary hyperten .ton. 10
rever tb
The traditi onal surgery performed for
ASD repairs ha been a medi an sternotomy with
Pericardi a! or Dacron patche , although a ri ght
anterolateral ubmamm ary subpectoral approach
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may be preferred by women for cosmetic
rea on . 11 • 12 There has been an increased use of
minimally invasive urgery recently, as ~n
alternative to surgery or percutaneou repa1r.
Intraoperative tran esophageal echocardiography
may be u ed to ensure proper closure of the
defect. Po toperatively, beta blockers and
anticoagulation reduce the ri k of atrial
troke respecti vely.
The
fibrill ati on and
perioperati ve mortality of such procedures
approac he Om-;o. 13· 14· 15· 16 Over the long term,
patients still have quite succe sful outcomes,
e peciall y with ongoing medical therapy, with
minor diffe rences in survival compared to the
popul ati on, and minimal ri k of needing
Minimally
mva 1ve
addi tional
surgery.
approache
may reduce the perioperative
morbidity and decrea ed hospital tay. Dr. K.
Finnie add th at clo ure of the ASD does not
reduce the incidence of recurrent atrial
arrh ythmi a such a atri al fibrill ati on. (Personal
co mmunicati on, 2008)
The FDA ha approved two percutaneous
devices, Ampl atzer Septal Occluder and the
Cardi oSEAL eptal Occlu ion Sy tern th at may
be u ed a an altern ati ve to treatment. 17 The
benefit of a transcatheter clo ure are that the
patient
avo id
cardiopulmonary
bypa ,
thoracotomy, and atri oto my. The outcomes are
exce llent and the tran catheter closure i largely
replac ing surgical clo ure in orne center for the
management of appro pri ate ASDs. Additionally
th e
peri operati ve
morbidity,
rate
of
co mplicati ons, and ho pita! tay may be reduced.
The percutanou method of ASD clo ure will
beco me the more preferred method of clo ure,
e peciall y in elderl y patient or tho e with
ignificant comorbiditie . 18•19 Thi nonoperative
device clo ure onl y can be used in patient with
o tium ec undum ASD (about 50-70 o of all
A~Ds ) an~ i not u ed in pati ents with o tium
pnmum, mu s veno u , or coron ary sinu atri al
eptal defect . The ASD mu st al o be mall or
moderately sized, ideally under 20 mm . Dr. K.
Finnie adds th at defects up to 39 mm can now be
repaired.(Per onal co mmunication, 2008).
Conclusion
Atri al septal
. . defect (ASD ) are abnorm a1
co mmum catJOns between the left and ri ~:> ht atri a

allowing mixing of the blood between these two
compartments. ASDs are the second most
common
congenital
lesion
in
adult .
Transcatheter closure of ASDs with the
Amplatzer Septal Occluder and the CardioSEAL
Septal Occlusion System are streamlining the
way ASDs are man aged. Decreased hospital
stay, decreased morbidity, and outcomes on par
or better than with surgery are popularizing the
minimally invasive procedure for the repair of
pecific types of ASDs.
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Commotio cordis: an important cause of sudden cardiac death in young athletes
Ashley Brown, Medicine 2011, ]erma Ashkanase, Medicine 2011, and Tiffany Kwok, Medicine 2010
Reviewed by Dr. Andrew Krahn
Although a rare occ urre nce, co mmoti o cordis is the second most common cau e o f sudden cardiac death in young,
hea lth y athlete . A slo w-moving proj ec tile (o ften a baseba ll or orne other sport eq uipment) trikes the co mpliant
precordium of an affected pati ent immed iately be fore the T wave of the cardiac cyc le, ca using a premature ve ntricu lar
con traction that induce vemri cul ar fibri ll atio n and cardiac arre t. Resusc itati on attempts are often unsucce sful and
urviva l rate are o nl y 15 %. Thi revi ew outlines the path ophy io logy and epidemiol ogy associated with co mmo li o
cordis, and addres es strategies that may help preve nt thi s life- threatenin g occurrence.

Introduction
Commotio cordi (CC), also termed "cardiac
concussion" , i a rare but devastating event
characterized by a eemingly inn oc uous blow to
the chest followed by s udden death. 170 ca e
have been reported in the U.S. Commotio Cordi
Registry (USCCR) since 1996, almost all of
whom are young male athlete with no pri or
history of heart abnormaliti es or dy function. 1·2
Although it is relatively rare, the eriou sness of
CC
warrants
investigation
into
it
pathophys iology and ubseq uent indication for
treatment and prevention.

Case Report
Th e patient described by Maro n et. al. (2005 )
illustrates many key features present in pati ent
affected by CC. A 22-year-o ld male who was
not wearing any protective chest gear was struck
directly over the precordium by a lacrosse ball.
He was extre mely athletic, had no prev iou Iy
reported health problems, and weighed 185 lb .
After bein g stru ck, he stumb led two teps and
fe ll to the ground . A trai ner immedi ately ran
onto the fie ld, determined that a pu lse wa. absent,
and initi ated cardi opulm onary res u. citati on
(C PR ). A sports med icine physician quickly
entered the scene with an automated ex tern al
defibrillator (AED) which detected ventricular
fibrill ation (VF).
T he AED deli vered an
appropriate defibrillation hock of 2001 within 2
minutes of the athlete's collap e.
Thi s
successfully terminated the VF and advised no
further shocks, however th e man's pulse did not
return , and CPR was continued by bystander

UWOMJ 77( 2) 2008 40

and 5 minutes later by paramedics. The man was
later pronounced dead in the emergency
department, approximately 1 hour after coll apse.
A che t x-ray revealed no rib fracture or other
injurie , and an echocardiogram revealed no
tructural abnormalitie of the heart. 3
A in the preceding case, most ca es of
CC in volve a yo ung male being truck in the
chest during an athletic event, immediately
initiating VF. Resuscitatio n i un uccessful m
4
the vast majority of case .
A case of co mmoti o co rdi s wa een m
London over 10 years ago. Attending phy ician
Dr. Andrew Krahn recount , "a young healthy
trucker, fat her of 2, [was] ti ghtening his load
with a cheater bar (bi g teel ratc het like bar for
the strap winch on a tran port truck)... at
Wellin gton and the 401. [He uffered a] minor
blow to the che t [with a] long delay to the
ambul ance." Unfortunately, thi man ultimately
suffered the arne fate as many commotio cordi
pati ent and di ed befo re the ambulance reached
5
him.

Pathophysiology
The pathophysiology of CC is not entirely
understood, although M adi as et al. (2006) have
dev ised a possible model to exp lai n it
occurrence. It ha been widely ob e rved that key
factors mu st ali gn in order to cause CC: a
sufficient but not exce sive force mu t strike the
precordium of a relatively compliant che t wall
just prior to the peak of the T-wave of the
.
card tac
eye le 1,2.6 ( ee p·tgure 1).
The force
strikin g the co mpli ant che t wall causes a rapid

increa e in pressure within the left ventricle.
This tretches the myocardium and activate
mechano-sensitive ion channel , re ulting in a
rapid influx of potassium ions and consequently
a premature depolarization of the myocardium.
This alone would cause depolarization of a
ingle beat, but would not be sufficient to cause a
u tained arrhythmia. However, within a period
a few milliseconds (15-30ms) before the peak of
the T-wave, so me of the myocyte of the left
ventricle can be depolarized , while others are
till refractory and are therefore unable to be
depolarized. Depolarization of only a portion of
the left ventricular myocardium results in nonimultaneous excitation, and thus fibrillation,
providing a 15ms window of vulnerability within
7
the cardiac cycle.
When one is struck directly over the heart,
the force i transmitted significantly within the
chest cavity due to mechanical compliance of
7
their che t wall. If the impact is at exactly the
rioht
time within the cardiac cycle, non-uniform
b
depolarization of the myocardium occurs,
re ulting in sustained VF and consequently
sudden death.
It i important to note that
structural damage to the heart and urroundin g
ti sues is not present in cases of CC due to the
low velocity of impact8 ; the pressure wave that is
transmitted to the left ventricle is the basis of the
pathology.
CC may occur in any healthy heart. 9
Athletes are more commonly affected because
they are at greater risk than the average per on of
sustaining a blow to the chest wall. Young
people are more commonly affected due to
increased compliance of their chest wall,
transmitting the force to the left ventricle more
easily than adults. Other than these two indirect
risk factors, CC requires no predisposing
features. It can theoretically happen to anyone,
but it is rare because very specific factors mu st
align within an extremely small window of
opportunity.

Population at Risk

.

The specific factors that coalesce to tngger CC
place a fairly narrow demographic at ri sk:
commonly, young male athletes appear to be the
most susceptible. Indeed, an analysis of 128
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ca e in the USCCR performed by Maron et al.
(1999) reported that 62 % of the events occurred
in male athletes of median age 14 years during
sporting competitions. This finding may be due
in part to sport' increased ri k of projectiles,
especially those that are rigid and/or possess a
den e core such as baseballs and hockey puck ,
hitting one's chest as well as the increased chest
wall compliance of young athlete described
above. 9
It is impottant to note that CC can occur
in non-athletes a well.
The USCCR has
recorded cases in which CC wa induced
fo llowing chest contact during uch seemingly
harmless event a horse-play, being struck with
a snow aucer, and a family pet colliding with a
8
ch ild 's chest. While these instances are thou ght
to be uncommon , they emphasize the point that
CC can affect almost anyone if all the etiological
factors are present.

Strategies for Prevention
Though cases of CC are considered to be rare
overall, there has been an increased incidence of
reports over the past two decades as recorded by
8
the USCCR.
Survival rates are dismal at
approximately 15%. In athlete this condition
has become the seco nd mo t common cause of
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8 11

in tant death. '
Since several factors are
in volved in the eti o logy of CC, everal meas ures
may be taken to reduce the incide nce of thi s
Both e mergency medical
tragic occurre nce.
techniques a nd porting apparatu s mu st be
examined and improved upon to reduce the ri ks
of deleterio us effect for athle tes.
M edi cal
profe ionals pre ent during sportin g event
well
trained
in
sho uld
no t onl y be
cardiopul mo nary re u citatio n and defibrillatio n
techni que, bu t should al o be edu cated regarding
the necessity of qui ck re po n e whe n CC is
u pected. It is thought that as i tance within 3
of collapse may improve the
minu te or le
outco me fo r so me pati e nts altho ugh it i not a
guarantee of succe s, as ev ide nced by the athl ete
in theca e tud y.
M ethods of alte rin g po rting equipme nt
and protecti ve gear to reduce the ri k of CC fo r
athlete have been uggested, most prominently
fo r baseball and
po rt
requmn g c hest
8
The implementati o n of
ofter
pro tectors.
ba eballs was proposed, but met with oppositi on
fo llow ing tri al th at de mo nstrated alte red bo unce
and velocity.
B a eball of an inte rmedi ate
den ity have been develo ped and are c un·entl y
being evalu ated as a co mp ro mi e between afety
and the integrity of the game. C he t protectors
have fall e n unde r scrutin y fo r bo th th eir
co mpo iti o n and the ir fun cti o nal capac ity. In a
tud y conducted by Doere r et al. (2007 )
examining c hest protectors, 38% o f the affli cted
athl etes were wearin g a pproved pro tecti ve c hest
padding. It ha thus been suggested th at the
dens ity and its distributio n within the protecti ve
gear be alte red to prov ide additi o nal defense. 8 It
1
also relevant to note th at of th e athlete.
wearin g ches t protectors, 25 o f 32 ex pe rie nced
di pl aceme nt of the ches t pro tector during the
12
cour e o f game pl ay.
A more effective mean
of keeping the pro tecti ve gear over th e cardi ac
silho ue tte ho uld be dev ised.

Conclusion
Co mmo ti o cordi s, tho ugh rare, i a partic ul arl y
deva tatin g cause of fa tality th at predo minantly
affect health y yo un g male athle te . It is cau ed
by a proj ectil e striking o ne's compli ant
precordium mo ments be fo re the T wave and
causes ve ntri c ular fibrill ati o n th at may not
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re pond to re uscitation . The ri sk of phy ical
and projectile contact inherent to sporting
compe tition
enhance
the
likelihood
of
usceptibility in athle tes, but non-athletes may
also be affected if the etiological factors
converge. Althou gh CC is considered to be a
relatively uncommon e ve nt, its ris ing incide nce
and tragic consequence nece sitate increased
awareness and preventive effort on several
levels.
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Feature Article
An overview of using cost-effective measures in preventing cardiovascular disease
Dinesh Bhayana, Medicine 2010
Reviewed by Dr. John Feightner
Cardiovascular di ea e carries a worldwid e economi c burden hi gher than any other chronic di sea e. The ag in g
populati on of developed nations have pl ayed a maj or ro le in the rapidl y increa ing the cost of deli verin g hea lthcar e.
In order to continue providing public healthcare to all citi ze n , the Canadi an government mu t loo k beyo nd increas in g
pending and focu on the appropriate alloca tion of available reso urces . Cost-ef fec ti ve meth ods o f hea lthcare deli very
should be con idered as a mean o f reducin g the gro win g eco no mi c burden o f cardi ova cul ar di sea e and other chroni c
di seases. Preventi o n of cardiovascu lar di ease has hown promi se as a co. t-e ffecti ve too l in the ex isting literature.
Further investi gation is required to develop a clear pi cture o f the rol e that preventi on will pl ay in reducing co ts and
delivering high quality healthcare to Canadian s. H owever, the exi stin g evidence should co mpel current and f uture
phy ician to appreciate the increasingly important rol e that cost-effective analy es will pl ay in shaping the future o f
our healthcare system.

Introduction
Healthcare spending by the federal and
provincial governments in Canada has come
under crutiny in recent years. Public discontent
and nation-wide anxiety have surfaced a the
co t of delivering healthcare climbs higher.
Once a solely economic and political issue dealt
with by policy makers in Ottawa, the topic of
healthcare pending is now seen in newspaper
and magazines in homes acros the nation. It has
long been recognized that among the reform s
needed to revive public support of Canadian
healthcare, control of spending must be a
priority. To this end, health policy makers
should systematically addres each determinant
of government spending that can be manipulated.
The three factors mo t influential in determining
healthcare pending in Canada are provincial
revenue, federal transfer , and the percentage of
1
the population over the age of 65. While
provincial revenue and federal transfers can be
controlled politically by manipulating fiscal
policy, the aging population is of concern to the
medical community. The mechanism by which
the aging population exerts its effects on
healthcare in developed nations, Canada
included, is the increased economic burden of
chronic disease? Thus, it is of utmost importance
that medical practitioners understand the nature
of chronic diseases and ubsequently apply
government resources in a cost-effective manner.

In 2001 , the two leading causes of death
and disability in developed nation were of
cardiovascular origin. 3 Ischemic heart di ea e
and cerebrovascular di ease ranked fir t and
second among t a variety of chronic conditions
that carry a large economic burden. The most
recent report by the Public Health Agency of
Canada estimated the economic burden of
cardiovascular disease (CVD) in Canada to be
over $18 billion in 1998, an increa e of nearly
4
12% since 1986. This escalating cost to
healthcare and society includes direct cost from
hospitals,
physicians,
procedures,
and
medications, as well as indirect costs from
disability and premature mortality.
Cardiovascular disease is a pnme
example of the pre sure that chronic di ease
places on healthcare spending. Patients may
require immediate high-quality radiographic
imaging, procedural intervention , and orne
Furthennore, CVD
length of hospital stay.
patients often require chronic maintenance by a
multi-drug regimen , routine follow-up including
blood work, and an array of behavioural
interventions aimed at reducing the ri k of
recurrence. It has been established that the ri k
factors implicated in CVD are modifiable prior
to the on et of disease and can reduce the ri sk of
~ first . eve nt and the need for costly
5
~ntervent~ons.
Thus, prevention of CVD by
mtervent10ns of proven efficacy, a outlined in
6
the literature , should decrease the overall burden
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of thi costl y di ease. This logic ha been
pro moted by health professionals for some time
bu t ha onl y recentl y begun to manife tin policy
changes. Thi
likely due to the fac t that
preventi on strategies are, unlike curati ve
trategies, characteri zed by immedi ate costs and
delayed benefits.7 Using data fro m cost-effecti ve
analyse to develop practice guideline
i
currently a complex undertakin g due to inherent
li mitatio n in the publi hed li teratu re. The wide
variation between studie in the in terventi on
cho en, methodology and interpretation ha
made
it
d iffic ult
to
im plement
the ir
recom mendations. However, by recogniz in g that
eco no mically sound in terventi on exist, current
medical tude nts and practi tioners can face
govern ment pre sure to prov ide cost-effecti ve
healthcare with innovati ve approache .

Overview of the evidence for cost-effective
prevention
Prim ary prevention i characteri zed by measures
that decrea e the likelih ood of a fir t occ urrence
of the di ease th ro ugh health pro motio n,
c reening for ri k fac tors, and ri sk fac tor
mod ification.7 A particular et of guideline for
primary preventi on of C YD 6 li ts ri k facto rs
that can be modified in several ways including
health
pro moti on,
poli tical
acti on,
pharmaceuti cal intervention, and behavioural
modi ficati o n. H yperlipidemi a, hyperten ion, and
cigarette smokin g are modifi able ri sk factors
with a variety of interventi ons th at are costeffecti ve if used approp riate ly. The most costeffecti ve ro ute of ac ti on is often attained by
choo ing in terventi on ta rgeted at the ri k profil e
of the ind ividu al patient in questi on. Therefore,
know ledge of co t-effecti veness i imperati ve to
th o e developin g and impl ementing appro priate
preventi on guidelines.
The reducti on of serum cholesterol leve ls
thro ugh primary preventi on has been show n to
reduce the ri sk of an adverse cardi ovasc ul ar
event. 6 HMG -CoA reductase inhibitors (statin )
and di etary modi ficati on are effecti ve tool in
lowering levels of erum low density lipopro tein
(LDL) in many populati ons, but their roles as a
cost-e ffective means of preventin g CVD vari e
by ri sk subgroup. In a rev iew o f cost-effective
analyses, autho rs fo und that tatin therapy is
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nearly 4 times more cost-effective in the primary
prevention of CVD in men with elevated erum
LDL and three other ri k factors than in men
with serum LDL elevated to the same degree and
no other risk factor present. Statin therapy in
both these po pul ations of men was still
considered
cost-effecti ve,
while
initiating
therapy in yo un ger women with erum LDL
elevated to the ame degree and no ri sk factor
8
was not cons idered cost-effecti ve. The initiation
of a low-fat, low-chole terol diet throu gh
physician counseling and mass- media health
pro moti on has al o been shown to be co teffecti ve in certain risk subgroup . In an
evaJu ati on of guideline fo r LDL target , authors
de termined th at employing dietary modification
as a primary preventi on mea ure i co t-effective
fo r nearl y all men regardless of ri sk subgroup
and wo men over the age of 55 .9
Hyperten ion can harply increa e the
ri k of C VD when multiple ri k factors are
pre ent, hence the need fo r aggressive
therapeutic target .6 In a large cost-effective
analy i
tud y of a number of diffe rent risk
fac tor intervention , two hyperten ion the rapi es
howed pro mi ing re ult .
While deemed
generally co t-effecti ve in multiple ubgroup of
on particular tud y, initi atio n of a B-blocker and
diuretic regimen wa fo und to be con iderabl y
more co t-effecti ve in pati ents with a y tolic
blood pre ure of greater than 160mmHg when
co mpared to those with a ystoli c blood pre ure
of 140 to 159 mmHg. A lso, the introducti on o f
po pulation-wide legi lati on to decrea the alt
co ntent in proces ed foo d proved to be extremely
co t-effecti ve
in
reduc in g
CYD-induced
di abili ty re lated to hyperte n io n. 10
Although the adver e health effects o f
cigarette smoking are le s spec ifi c to C YD than
hyperlipide mi a and hypertension,
moking
ce.. ati ~n l s of hi gh ptiority in primary
prev~n.t w n . In o ne tud y, moking ce ati o n by
ph ysic ian counselin g wa fo und to be a mo re
cost-effecti ve approac h to primary preventi on of
C YD than therapy fo r hyperlipide mi a o r
h
. 8
yperte.n 10 11 . ~h e ma s medi a approach o f
promotmg moking ce . ati on wa fo und to be
less cost-effecti ve than ph y ician coun ' eli no to
those pati ents with more th an one oth r ~i k
factor. Al o, moking ce sati on wa found to be

le cost-effective than dietary modification m
the overall prevention of CVD. 12

Discussion
There exists a strong body of evidence for the
cost-effectiveness of measures in CVD
prevention. Despite the difficulties in clinically
applying co t-effective analyses, the current
body of literature ha provided a solid basis upon
The
which further investigation can build.
overview
provided
here
illustrates
the
importance of targeting groups of patient based
on their risk profile and utilizing appropriate
primary prevention measures to modify ri sk
factors . While cost-effective tools for primary
prevention should be used, each intervention has
a threshold of risk subgroups outside of which it
is no longer cost-effective. Thus, the use of a
single prevention algorithm would result in
overshooting prevention and wasted resources or
under hooting prevention and increased disease
burden.
An adaptive and patient-centered
approach i
necessary to pro peri y apply
preventive measures to the variable population of
individuals at ri sk for CVD.
While CVD currently accounts for the
greatest economic burden to the healthcare
system, a preventive revolution aimed at
modifiable risk factors in the Canadian
population will likely have widespread influence.
The risk factors for CVD are implicated in a
wide array of chronic di seases including
respiratory, endocrine and hepatic conditions, as
well as a number of malignancies. As the burden
of these chronic diseases continues to put
pressure on the healthcare ystem, the need for a
strong preventive medicine agenda becomes
increasingly apparent. The role of economics in
understanding the effective use of prevention
will continue to grow a challenges in modeling
and investigation are overcome.
Thus far,
current and future practitioner should be aware
that research supporting the cost-effectiveness of
primary prevention in CVD exists and that
studies in this field may soon move from balance
sheet to bedside.
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Feature Article
Health Canada Ban on Ephedrine - A Post-ban Assessment of Effectiveness
Is/w inder S. Chattha, Medicine 2011
Reviewed by Dr. David Masse[
Ephedrine i the pharmacolog icall y active alkaloid found in extracts from the Ephedra genu of shrubs nati ve to
Central A ia. It pharmaco log ica l propertie have been put to u e in variou weight-lo s products, athletic enhancer s,
deconge tants and bronchodi lators. D ue to i t primaril y negati ve card iovasc ul ar effec t , an inco mpl ete ban ha bee n
pl aced by Health Canada on ephedrine u age, whi ch i now restricted to use so lel y in nasal deconge ti ves and
re tri cted to 8mg doses. Ephedri ne bans have been ucce sfu l i n reducing ephedrine ales, however it ha not bee n
effecti ve in changing the widespread beliefs o f co ll ege tudent or eli mi nating ill egal ephedrine u age. T he ban also
doe not take into accoun t the ynergi tic effect of ca f feine and ephedrin e. A dd iti onal re earch into the ynergi sti c
effects of ca ffeine and ephedrine should be conducted in order to address the need o f a full ban in order to protect
again t cardi ova cul ar co mplicati ons.

Introduction
Governmental restnctiO n on the usage of
pharmacologically ac ti ve ub tance can be
tri ggered by newly uncovered scientific
ev idence, increasing public awareness, politi cal
moti vation , or a co mbination of these factor
among others.u
Post-re tricti on data JS
co mmonl y lacking in regards to effecti venes o f
po licie , implementation, and regul ati on. Thi
article a esses the po t-re triction literature in
regards to the 2001 Health Canada re tricti on on
the usage of ephedrine to determine the
effecti veness of the inco mpl ete ban.
Ephedrine i
the pharmacologicall y
acti ve alkaloid found in ex tracts from the
Ephed ra genu s of hrub nati ve to Central A ia.
Ephedrine is a sym(1ath omimetic amine, whi ch
exert it affects primaril y th ro ugh interacting
with a - and ~ -adrenergic receptors which
medi ate sympath eti c responses. It also stimul ate
the release of endogenou catec ho lamine and
inhibit there reuptake fro m the synapse. 3
Ephedrine' s ac ti on on the ·ympatheti c nervo us
sy tern have been put to use in vari ous weightlo product , athl eti c enh ancers, concentrati on
4
aids, deconge tants and bronchodil ators.
Several adverse cardi ac event have been
docum ented from ephedrine usage: the mo t
evere includin g myocardi al infarcti on, troke,
and sudden death .5 In 200 l , after 60 adverse
events were reported in Canada, Health Canada
restri cted the sale and dosage limit of ephedrine
products. Eph edrine is now authori zed for u e
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onl y as a na al decongestant and at a maximum
dose of 8 mg with no more than 32 mg in a 24 hr
pen.o d .6
It i important to a ess the change in
ephedrine u age and ephedrine-related adver e
events after th e re tricti on has been put in place
in order to evalu ate the effectivene
of uch
legislati on as it is a co mmon form of prevention.
This article look at the literature co ncerning
ephedrine
re lated
adver e
event
and
epidemiological data in order to asses the
rati onale and effecti vene of Health Canada ' s
inco mplete ban on eph edrine products.

Pharmacological Properties
Ephedrine'
ympatho mimetic
effec t
are
medi ated th ro ugh interac tions with a - and ~ adrenergic receptor . It al o timulate the
re lea e of endogenous catecho lamine from
neuro ns through increasing the number of
ve icle relea ed during each action potenti al and
al o delays their reuptake fro m the synap e It
affinity to ~ -receptor is greatest for ~1 followed
by ~2 then ~3 recepto rs. 7 Ephedrine produces
positi ve ionotro pi c e ffect and chronotropi c
effects. It i a powerful vasocon trictor and i
arrythmogenic.
Ephedrine readil y eros e the blood-brain
bani er produc in g central nervo us y te m effect
resembling tho e o f a mphetamines. Ephedrine
has an 85% bioavail ability, half life o f three to
ix hours, and IS removed through renal
excretion. 8

Adverse Effects
Before ephedrine re triction were put in place in
the US , The American Association on Poi on
Control Centers, in 2003, reported that ephedrine
related adverse events accounted for more th an
one-half of all reported dietary supplement
related adverse reaction
while ephedrine
product ales accounted for less than 1% of the
9
marketplace. This di sproportion highlights the
concerns regarding ephedrine usage.
The mo t common reported adverse event
a ociated with e~hedrine usage is hypertension
and tachycardia.' Ephedrine use has al o been
associated with both i chemic and hemorrhagic
stroke, cardiac arrhythmias including ventricular
tachycardia,
coronary
vasospasm,
acute
myocardial
infarction,
tachycardia-induced
cardiomyopathy, and udden death . 11
Effectiveness of Incomplete Ban
Ephedrine products have seen increasing use in
the past two decade for the unapproved
purposes of weight loss and improved athletic
performance. Ephedrine increase the rate of
weight loss by 0.6 kg per month in comparison
to placebo. When combined with caffeine, the
rate increased to 1.0 kg per month greater lo
12
than with placebo.
In the athletic arena,
ephedrine and caffeine alone do not have
significant effects on oxygen consumption,
carbon dioxide production, or time to exhaustion
in comparison to placebo. However, when taken
in ~ombination, ephedrine and caffeine have
shown to produce up to a 20% to 30% increa e
m athletic performance as seen throu gh
imr>rovements m run times and
trengthtrai)1ing.1 3
Although Health Canada has limited the
dopage of ephedrine, when taken in combination
with caffeine, a low dose can produce effects
mjmicking those of moderate (30-40 mg) to high
14
d~sages (70-80 mg) of ephedrine. This is of
p,articular importance as ephedrine combined
y;ith caffeine produces greater weight loss and
fmproved athletic performance, the primary
reason for u e among females and males,
. 1y. 15
respective
The protective action of the 8 mg per
dose, 32 mg/day maximum dosage has been
found to have limited value as The As ociation

of Food and Dru g Officials (AFDO) states that
serious adver e effects to ephed rine products
16
may occur at do age of 24 mg per day. Lifethreatenin g adverse reaction s have been reported
17
to occur with doses of 1 to 5 mg. AFDO is also
concerned that setting a dosage limit may fa lsely
imply th at a safe dose exists.
Several States in the US have issued a
complete ban on ephedrine products. This
legi lation res ulted in a significant reduction in
methamphetamine usage (prod uced by ephedrine
throu gh che mi cal reduction) a
well a
18
methamphetamine related hospital admissions.
Ephedrine ales through retail outlets have al o
dropped si nce the ban. 19 In 1997, National
Collegiate Athletic A sociation (NCAA) iss ued a
ban on all ephedri ne co ntaining sub tance .
Desp ite these bans, studies have shown an
increasin g trend in ephedrine usage amongst
college athletes. In 2001 , a study of NCAA
athletes howed ephedrine usage at 3.9%. 20
Usage has been ri ing since 1991 , and continued
21
to rise even after the ban was put into place. A
2006 study by Bents and M ar h (22) showed th at
among members of an NCAA hockey team,
59 .0% reported that the ephedrine ban would
make them less likely to use the substance, while
40.3% reported that they would u e banned
substances to play at hi gher level.
De pite the restrictions placed on the
usage of ephedrine, ephedrine products are easily
obtainable throu gh products so ld a
nasal
decongestants or via the internet? 3 Federal
authoritie are getting involved a ephedri ne can
be
chemically
reduced
to
produce
methamphetamines. During 2006, the most
frequently smu ggled prec urso rs fro m other
countries
into
Canada
was
ephedri ne.
Approximate ly 33.8 million ton s of imported
ephedrine is b in g used by manufacturer each
year to create non-methamphetamine product
for sale in Canada? 4

Conclusion
With the negative cardiovasc ular effects of
ephedrine use, there is a clear methodol ogy
behind the ban of ephedrine substances.
Although Canadian data do not currently ex ist,
US data pre- and post-ban has hown th at
although the legislation has not completely
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eliminated non-approved usage, it ha decreased
its overall incidence however not among select
popul ati on such as college athletes. As urvey
re ults have shown, ephedrine u age most
co mmonly begins during hi gh schoo1. 25 Further
reducti ons in use may be attain able through
educati on of the adverse effects ' bein 0u
implemented at the high schoo l and college
levels, targeting those e pec ially at risk fo r
ephedrine usage: athletes and weight conscious
individuals.
The cardi ovascul ar co mplicati ons of
ephedrine use in co mbin ation with caffein e,
requi res further scientific research as few tudi es
exist on thi s topic. If a synergi tic effect on
producing cardiovascular compli cati ons is
repeatedly fo und such as tho e shown by Persky
et al. (26), the 8 mg per dose guideline hould be
reconsidered.
Cardiovascular events are bein g reported
at do age lower th an 8 mg. The benefits of
usi ng ephedrine in ph armaceutical products need
to be weighed against the risks associated with
its use, both pharmacological and no npharmacological,
as
over
the
counter
medications are a source of ephedrin e use fo r
7
non-approved purposes ?
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Feature Article

Takotsubo Cardiomyopathy
A Review of Clinical Features, Pathophysiology and Management
Xiangning Fan. Medicine 2010
Reviewed by Dr. Patrick Teefy
Takotsubo cardiomyo pathy i a recentl y described and poorl y recogni zed clinica l entity perhap best known for its
nt e levati on myocard ial in fa rcti on (STEMI) and non-ST -seg me nt elevati o n myocardi
al
abi lity to mimic both ST-seome
b
.
.
.
in farc ti on (NSTEM I), especia ll y in po t-me nopausa l women and fo ll ow ing stressful situati ons. Becau e of thi S, It IS
an important co nsidera tio n in the d iffe renti al diag nos is fo r patients presentin g with sy mpto ms and signs consistent
with ac ute coronary sy nd rome (ACS). Ap ical ba ll ooning of the left ve ntric le see n o n ec hocard iograph y or left
ventri cul ogram with preserved motion or hyperki nesis of the ba al seg ment i the s ignature appearance o f thi
co nditio n; however, a di ag nos is ca nnot be made until coronary artery d i ea. e is rul ed o ut with a ngiograph y. The
pathophysio logy of thi co nd iti on ap pear to be re lated to tran ie nt myocardial tunnj ng econdary to hi gh level of
circul ating catec holami nes. T hi s appears to be via a di ffere nt mec hani sm tha n th at seen in response to myocardial
ischemia, but the exact mechani sm re mai ns un known. Although Takotsubo cardi o myopathy is thought to compri se
2% or less of all presentati ons of ACS, thi i thought to repre ent an underes timate of the true incide nce. Increasing
aware ness of the cond itio n as well as the trend towards urge nt ang iography and primary PC I a the favo ured treatme nt
o f ST EMI are expec ted to reveal prev iously undi agnosed or rni di agnosed case .

10

Background
1

In 1990 , Satoh and colleague
described a
unique cardiomyopath y whi ch has ince beco me
known
as
"T akotsubo
cardiomyo pathy,"
" transient apical ball ooning," "stres -induced
cardiomyo path y," and "broken heart synd ro me."
Classically, this co nditi on manifests itself as
acute-on et retrostern al chest pain , shortness of
breath , and EKG changes consistent with
transmural anterior wall infarction, most
commonl y ST- egment elevati on in
the
2 4
appropri ate precordi al lead . - It is seen most
comm onl y, but not exclu sively, in po tmenopau al wo men who have ex peri enced a
udden ph ys ical or e moti onal tress, and is
acco mpani ed by a characteri sti c appearance of
the left ventricle on echocardi ograph y or left
ventriculograph y
and
the
absence
of
he modynamically igni ficant coronary artery
di sease in the distribution of the left anteri or
descendin g (LAD ) artery. 5·6
T akotsubo
cardi o myopath y,
th erefore,
represents
a
di agnosti c diffi culty in that it mu st be rapidl y
and acc urate ly di stin gui shed from anteri or
STEMI in order to fac ilitate correct c linical
dec ision-making regarding therapy for th e
patient with ACS. S ince 1990 , the clini cal
features of Takotsubo cardio myo path y have been
described 7, and di agnosti c criteria established by
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vari ous groups 6 ·8 - ; these invariably emphasize
the tran ient and rever ible nature o f Takot ubo
cardi omyopath y, and the ab ence of signifi cant
coronary artery di ease, ruling out ischemic heart
di ease as a cau e of ventri cular dysfun ction .

Clinical and Investigative Features
Much of wh at i known about the clinical
presentati on
and
course
of
Takotsubo
cardi omyo path y deri ve from publi hed case
reports.
Since its initi al de cription in the
literature in 1990 , Takot ubo cardi o myopath y
has been reported with increasing freque ncy both
in and outside of Japan. There is a mall rise in
serum troponin and creatine kinase levels with
imil ar kinetic to th at seen in Acs _2A·6 High
plas ma catecho lamines are found in a maj ority of
patient at presentati on; however, their role in
the pathogenesi remains poorl y under tood and
these are not generally measured unles there is
concern about pheochromocyto ma. It i not
clear whether eri al measurements are of value
for clinical deci ion-making. '' -' 4 Pati ents with
Takotsubo cardi omyo path y, because they do not
have signi ficant co ron ary artery disease, are
thought to have a more favo urable clinical
course than the ir peers pre enting with MI. 15
At initial pre entation, it is o ften difficult
to differenti ate T ako t ubo cardiomyo path y from

STEMI via electrocardiography, as ST- egment
elevations in the appropriate precordial leads are
een in electrocardiograms (EKG ) performed on
both set of patient . 16·17 A the hyper-acute
phase pas e , the EKG will evolve, often
revealing deep T wave inversion s in the anterior
lead and QT prolongation. 1 Much attention ,
therefore, ha been devoted to identifying and
characterizing the sen itivity and specificity of
EKG pattern which may suggest STEMI over
Takotsubo cardiomyopathy, or vice versa.
Ogura and colleagu
ugge t that a con tellation
of EKG findings -namely, absence of reciprocal
change , absence of abnormal Q wave and a
ratio of the ST egment elevations in leads V4-6
over elevations in Vl-3 > 1-may be highly
pecific for Takotsubo cardiomyopathy when
19
the e exi t together.
Inoue and colleague
confirmed that the ab ence of reciprocal changes
and abnormal Q waves on EKG may be helpful
in differentiating between patient pre enting
with Takot ubo cardiomyopathy and those with
anterior MI secondary to occlusion of the
0
proximal LAD ? Bybee and colleagues ugge t
that patients with Takotsubo cardiomyopathy
typically pre ent with lower ST
egment
elevations than their peer who present with
bona fide anterior MI seco ndary to occlu ion of
the
LAD. 15
However,
a
the
electrocardiographic
differences
between
Takotsubo cardiomyopathy and anterior STEMI
are subtle and easily mi ssed and the clinical
features of these two conditions overlap, urgent
coronary angiography to rule out ignificant
coronary artery disease and echocardiography or
left ventriculography to demonstrate the
characteristic apical ballooning remain necessary
for diagno i .
The characteristic appearance upon
echocardiography or left ventriculography of the
heart
of
a
patient
with
Takot ubo
cardiomyopathy i of dilation of the apex of the
left ventricle with pre erved_ or ~~fer-contrac~ion
of the ba e of the left ventncle.- The ventncle
is said to re emble a Japane e octopu trap, from
which the name derives.
More recently, a
variant form of Takotsubo cardiomyopathy ha
been described in which the ventricular dilation
occurs not at the apex of the left ventricle, but in
20
the mid-ventricular segment.
Takotsubo

cardiom yopathy involving the right ventricle ha
21
also been re ported in the literature.
An
inverted pattern ha
been de cribed m
as ociation with central nervous y tern injury
?2.?4
and pheochromocytoma.- -

Pathophysiology
In contrast to the clinical course of anterior MI,
the impairment in left ventri cu lar function een
in Takot ubo cardiomyopathy i transient, and
typically recovers within 2 month s of initial
pre entation .
Tho ug h this tran sient left
ventricular d ysfunc ti o n is thought to represent
myocardial stunning of the affected portion of
the left ventricle, wi th or witho ut transient
myocardi al ischemi a, muc h remain unknown
about the pathophysiology of Takot ubo
cardiomyopathy.
Recent
attempt
to
exp lai n
the
pathophysiology have settled upon high levels of
circulating catecholamines a
the
likely
pathology underlying thi cardio myopathy. One
explanation i
that
ystemic release of
catecholamines following a stressful event
result is suffici e nt to tun the myocardium. Du e
to the high concentration of adre ne rgic receptor
in the apex of the left ventricle, thi regio n is
preferentially s usceptible to catecholamine2
induced tunning. A Circulating catecho lami ne
are hypothesized to produce left ventric ular
dysfunction via a mechani m differe nt from that
12 25
seen in ischemi a ' , altho ugh Takot ubo
cardiomyopathy ha
been
een fo llowi ng
26
coronary artery va o pa m
and tra n ie nt
catecholamine-mediated
vaso pa m
may
4
contribute.
Inte re ting ly,
Takot ubo- like
cardiomyopathy ha
been
reported
with
pheochromocytoma, thereby le ndin g credence to
the
ugge tion
of
catecholamine- induced
. 1 dys f unction.
. 2?-·-') 7 Mo re recently , Ako
myocar d 1a
and co lleague have noted imilarity between
Takot ubo-like
cardiomyopathy
and
left
ventricular dy function following ac ute brain
injury, thu rai ing the po ibility of a hared
pathophysiology. 28
Alternatively, Iban ez has proposed that
the phenomenon of Takot ubo cardiomyopath y
can be better ex plained by occlu ion of the
proximal or mid-segment of an exception ally
long LAD which wrap around the apex of the
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left ve ntricle, res ul tin g in i chemjc myocardi al
dysfunction,
fo ll owed
by
pontaneous
29 -3 1
.
h"
h
h
.
.
reper f us1on
; t 1 ypot ests 1 not as we 11 accepted, but may explai n how Takot ubo
cardiomyopathy may develop in patients without
significantly elevated plasma catecho lamines.
Impaired microvascular fu nction may al o be
present and explain the anatom ic pattern of
ventric ul ar dy function extendi ng beyond the
territory of the LAD.32
A genetic contribu tio n to the etiology
and/or
usceptibi lity
ha
been
recentl y
ugge ted 33 , but ha yet to be conclu ively
prove n.

Management
There ho uld be a high index of su ptc io n fo r
this disorder e peciall y in o lder fe males
fo llowin g a recent emotio nal up et o r ph ys ical
tress. Differentiatio n fro m ACS can be di fficult.
If prompt acces to a cardi ac catheteri zati o n
laboratory i available , it is the preferred
approach to acc urately diag nose thi s di sorder and
rul e o ut myocardi al in fa rcti o n. Understandabl y,
if a catheteri zati o n laborato ry is not readil y
available, o rne patients may be di ag nosed wi th
STEMI, and, as a re ult, receive thrombolyti c
therapy.
Emergency echocardi ograph y may
have a ro le in imagi ng the anato mic dy functio n
characteristi c of Takotsubo cardi o myo path y.
Initi al therapy is u uall y suppo rti ve in nature 4-6 ,
and con ist of a pirin , ACE inhibitor , beta
blocker , and/or calcium channe l blocker 34 ,
tho ugh the ir use i
o mewhat empiri .
Anti coagul ati o n with heparin ( w itchin g t
Coumadin) is often used give n concern about
deve lopment of in tram ural th ro mbu s in the
ball ooned apex. This can be sto pped o nce the
ventric ul ar functi on norm ali zes in 1-2 month .

econdary to embolism of an extstmg apical
47
thro mbu s46 and left ventricular w all rupture.
The
mortality
attributed
to
T akotsubo
cardio myo path y i 1%? Although the o bserved
rate of recurrence is low, it is impo rtant to note
th at lo ng term fo llow-up of patients with
Takot ubo cardio myopath y i limited ?

Summary
T akot ubo cardiomyopathy is increasingly
recogni zed a a cause of ac ute chest pain and
dys pn ea mim icbng ACS . It is di tingui hed
fro m anterior MI o n the basis of characteristic
and/or
ventriculographic
echocardi ographic
findin g , namely, left ventricle wall motion
abno rmaliti e , in the absence of critical coronary
arteri e
teno e .
The typical wall motio n
abno rmality seen is octo pu -po t shaped dilation
o f the apical and midpo rti o ns of the left ventric le,
with normal mo tio n or hypercontrac tio n of the
base of the left ventri cle, altho ugh variant fo rm
A lthough the preci e
have been de cribed.
patho physiological mechani m which produces
these changes in the ventric le i unknown, recent
ugge tio n of tran ient myocardi al tunning
secondary to hi gh level
of circ ulating
catecholamine appear con i tent with clini cal
observatio n . O verall , pati ent w ith T akotsubo
cardi o myopath y hav a favo urable prog no i , but
related to
may ex perience complicatio n
tran ient left ventricular d y func ti o n whi ch
require supportive care.
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Feature Article
Genetic Basis of Coronary Artery Disease
Matthew Lanktree, Medicine I PhD 2012
Reviewed by Dr. Robert A. Hegele
While fanuly history i a strong ri sk factor for coronary artery di ea. e (CAD), the actual molecular basis has not been
chara terized in mot ca e. In 2007, four genome-wide a ociati on studi es (GWAS) reported strong as ociation (up to
22
p=l0- ) between a region of chromo orne 9p2 1 and CAD. The high ri k genotype was found in up to 30% of people,
creating the potential for a clinica l genetic te t to a ist in the prediction of a patient' ri sk for CAD. However, the
reported effect ize of the association is modest (odds rati o - 1.3) and incorporati on into a clinica l setting may be
premature. Thi paper reviews the adva nce in human molec ular geneti c allowi ng for the production of GWAS , and a
re ult of the four GWAS of CAD relea ed in 2007. In addition, these four GW AS are meta-analyzed and the pooled
ignifica nce and effec t size e timate are ca lculated. A of yet, there is no explan ati n for th e basi s of the assoc iati on of
thi s region of chromosome 9 with CAD. The consistency of the as ociati on aero populations sugge ts a biologica l
mechani m i re ponsible. Perhaps the greate t co ntribution from the assoc iation i yet to come, a further studie
identify the mechani tic ba is for the lrong assoc iati on, possibly lead ing to additional in ights into the progre ion,
prevention , and treatment of CAD.

Completion of the sequencing of the human
I 7
.
genome wa
a monumental ac h1evement. ·Molecular re earcher now take for granted the
information provided by the seq uence, however
the clinical application are not immediately
obvious. A limitation of the Human Genome
Project wa that it produced only a s ingle
"reference" equence. But in order to identify
new di sease causing mechanisms and cures for
di ea e, we need to go beyond the " reference"
and characterize the differences between our
genomes, and in turn the effect that these
differences
have. The
Human
HapMap
3
consortium and recent genome-wide association
studies (GW AS) have set out to capture the interindividual difference that are associated with
di sease proce se , including coronary artery
di sease (CAD).

Basics of Genetic Variation
Every human nucleu contains 46 chromo omes
organized into 23 homologou
pair : 22
autosomes plu s a sex chromo orne inherited
from the mother and 22 autosome plu s a ex
chromosome
inherited
from
the
father.
Chromo orne are made of DNA and can be
divided into gene , which are area that are
transcribed into mRNA then tran slated into
proteins, and intergenic regions, which can
contain tran cription regulating elements. Only
-5% of the genome is thought to be tran lated

ultimately into protein ; the remainder i ilent.
Mo t of the genomic sequence (-99.5 %),
whether coding or silent,
invariant between
individual .
The mam form of genomic difference
between people is the s ingle nucleotide
polymorphi sm (SNP, pronounced " nip"). A
SNP is a ingle ba e pair change in the DNA
sequence that, by convention, occurs in at least
5% of the population. With the human genome
equence known,
the
location
of any
polymorphi sm can be preci ely determined. Each
SNP i repre ented by two allele , together
called a genotype, with one all ele re iding on
each homologou chromosome. SNPs are the
most ba ic and ea ily measured forn1 of genetic
variation that might lead to inter-individual
differences at the level of the phenotype. A gene
can contain zero to many SNP : on average
SNP occur about 1 in every 300 to 400 base
pair , and gene range in size from le than a
thou and to more than two mi ilion ba e pair .-1
DNA i replicated extremely effectively with
very few error . Thu s, SNP are generally
inherited from our parents rather than occurring
pontaneou ly. Occasionally , a de novo meiotic
mutation increa es in frequency in ucce ive
generation to become a SNP, e pec ially if it
confer a survival or fitne advantage. Because
they are inherited , SNPs can give insight into the
hi tory of the surrounding block of the
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chromosome. If an unknown sequence variant
that alters disease risk resides within the same
block of DNA a a SNP, known a a haplotype
block, we can indirectly identify the ri k
equence variant by examinin g the co egregation
of the SNP with the disease. In associati on
studie , researchers compare the prevalence of
alleles of SNPs in cases and contro l to
potentially identi fy a ri k block.
Early in the twenty first century a new
technology called "SNP chip ", also call ed
arrays or o li gonucleotide microarrays, were
SNP
chips
permit
introduced.
These
si multaneous analysi of up to a million SNP
genotypes aero
the genome in a sin gle
experiment for a single DNA sample. Le s than
five year ago, u ing older technology a hi ghly
motivated grad uate student might produce 400
genotypes in a day. Using SNP chips, large
genetics centres can now perform GW AS to
measure millions of variants in thou sands of
case and controls in a few days. In 2007, SNP
chips were co mbined with the GW AS approach
to di cover new chromosomal regions that were
as ociated with a range of common di sease
including rheumatoid arthritis, Crohn 's di ea e,
type 1 diabete , type 2 diabetes, and CAD.

Genomics of CAD
CAD is the leadin g cause of death among North
Americans. Smoking ce sation , weight and
Publication
date

Number
of cases

He lgadotti r et al. 6

Jun e 2007

7

diabetes
management,
low-dose
aspirin,
hyperten ion control, and lipid-lowering therapy
can substantially reduce the ri sk of CAD. Many
rare single-gene di sorders have been discovered
that substantially increase the ri sk of CAD but
are only present in a small proportion of the
population (eg. familial hypercholesterolemia
due to point mutations found in 1 in 500 people).
Heritability studie of CAD and myocardial
in farc tion
(MI)
indicate
th at
common
usceptibility gene va1iants (perhaps found in 3050% of people) are an important part of CAD
n. k' . 5

Synthesis of large GWAS in CAD from 2007
Four GW AS from 2007 , performed in samples
from several different populations, all howed
th at a region on the hort arm of chromosome 9
(namely 9p21) was associated with increased
CAD risk. The fo ur studies reviewed in this
6
paper will be referred to as Helgadottir ,
McPherson7 , WTCCC 8 and Samani 9 for the
remainder of the paper. The chromosome 9p21
results from these four GW AS will be metaanalyzed.
Study samples: Helgadottir tudied pati ent from
Iceland, an isolated population, to ens ure genetic
and controls.
homogenei ty between case
McPherson
studied
European
Caucasian
participants from the Ottawa Heart Study,
African American and Cauca ian participants

4587

Numbe r
of
co ntro ls
12767

Icelandi c

Jun e 2007

3989

18808

Mi xed

WTCCC~

June 2007

1926

2938

Samani et a/.9

Aug. 2007

875

1644

Great
Brita in
Caucasian
German
Caucas ian

11 337

36 157

McPher on et al.

Combined

Popu lati on

Genotypi ng
method
Ulumina
Hap300 array
C ustom an·ay
Affy metrix
500k array
Affymetrix
500k array

Number
of SNPs
examined
305 953
75 000
2*
377 857t

272 602t

Table 1. Studi es described in thi s pape r. Ab bre viati o n - WTC C : We lco me Trust Ca e Contro l Con ortium·
SNP: Si ng le nuc leotide po lymorphi sm. *initial sa mpl e of 322 cases and 3 12 contro l , re pli cati o n o f re ulls p~0 .025
in 1.658 ca e ~ ~d 9380 controls, 2 9p2 l SN P performed in re mainin g . ubj ect . tS NPs tha t did not meet Hardy
We mbcrg equ ll1 bnum, had a rrun or a ll ele freque ncy< l %, <98 9l S NP ca ll ra te, or were on X c hro mo orne were
re moved .
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from the Athero clerosis Ri sk in Communitie
Study, Dani h Cauca ian participants from the
Coppenhagen City Heart Study, and a multi ethnic ample from the Dallas Heart Study.
Control were carefully selected in order to
ensure equal representation in case and control
group . Samani cases and control were collected
from a genetically homogenou
region of
Bavaria in
outhern Germany . WTCCC
exten ively te ted for difference in background
allele frequencies due to the ethnicity of study
subjects. Twelve regions from aero the genome
were found to be heavily influenced by
geographic variation and were thus removed
from the WTCCC and Samani tudie .
Study subj ects: All tudie included male and
female . The Helgadottir ca es were diagno ed
with aMI before the age of 70 in males and 75 in
female . The McPher on ca es underwent
coronary artery bypass grafting, coronary artery
angiography, or care for acute MI before the age
of 60. The WTCCC case had a documented
history of MI or coronary revascularization
before their 66th birthday. Finally, the Samani
cases were diagnosed with a MI prior to the age
of60.
Statistics: The WTCCC and Samani studie
reported odd ratios comparing individual with
two ri sk alleles verse no ri k alleles and
individual with one ri sk allele verses no ri k
alleles (genotype odd ratio). The Helgadottir
and McPher on studies reported odds ratio by
comparing the number of the ri k alleles pre ent
in cases to the number of risk alleles pre ent in
controls (allelic odds ratio). It is poss ible to
calculate allelic odds ratio from genotype odd
ratio (each homozygote contributes two alleles
and each heterozygote contribute one of each
allele) but not vice ver a; hence, the current
meta-analysi u es allelic odd ratio. The four
GW AS did not assess the exact same SNPs due
to different genotyping technologies, but all
ignificantly a ociated SNP were located in the
same haplotype block (Helgadottir, rs l0757 278 ;
McPheron, rs l0757274; WTCCC, rs6475606 ;
Meta-an alysis
wa
Samani ,
r 4977574).
performed u ing the Mantel-Haenszel method,
which create an estimate of the pooled odd
ratio as uming a fixed effect model using the
raw data from the individual studies. Haplotype

block
tructure wa
obtained from the
HapMap
International
VIa
Consortium 3
.
10
H ap Iov1ew.
Synthesis findings: The odd ratio, confide nce
interval and chi- quare p-value found for the
SNP on chromo orne 9p21 are show n in figure
1. The Mantel-Haen ze l umm ary effect e timate
aero all four tudie i an odds ratio of 1.30
(95% C.I. 1.25-1.36).
Odds Ratio
(95% Confidence Interval)
0
Helgadottir

0.5

1

1.5

2

P = lxl0·20

A vs 6

McPherson

p

=1xlo· 22

Avs B

WTCCC

p = 4xlo- 14

AA vs BB

Saman i
AA vs BB

Combined

p = Sxlo· 7
p = 4xlo- 69

Avs B

Figure l. Fore t plot of odd ratio obta ined comparing
9p1 l SNPs with CAD from the four GW AS a nd the
combined effect e timate u ing Ma ntel-Hae n ze l metaanalysi s. A vs. B indi ca tes alle li c odds rati o a nd AA vs.
BB indi cates genotypi c odd. ratio.

Discussion
Thi meta-analysis of 4 large GWAS empha izes
the trength , significance, and replicability of the
association on chromo orne 9p21 with CAD.
The significance level from the combined
analysis, p = 4xl0-69 , is a result rarely seen in
statistical analysi of biological sy tern , and i
approximately equivalent to the probability of
flipping a non-loaded coin and obtaining head
227 time m a row. However, despite the
overwhelming stati stical relationship, it i
important to recall the difference between
tati tical ignificance and clinical significance.
The level of confidence that a differen ce ex ist
between the allele frequencies in CAD case and
controls implies little regarding the clinical
implication of thi s difference. An odd ratio of
1.3 i hardly suffici ent for a clinician to
introduce any new ri sk factor test or imaging
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method into hi /her deci ion making fo r a ing le
patie nt. In compari on, smoking confe r an
11
increased ri k of MI with an odd rati o of 3.0 .
Simpl y taki ng a famil y hi tory verbally and
findin g out that a parent had heart disease under
12
age 60 confe rs a 2-fold inc reased ri k. It is
ex tre mely di ffi c ult to plumb the impo rtance of a
ri k of an odd rati o of 1.3 de ri ved fro m a SN Pbased assay on an indi vidu al pati e nt.
So why is the geneti c finding important?
Perhaps thi di covery will ultimate ly contribute
to our under tandin g of the pathogene i of
CAD. Wh at expl ains the inc redibl y tro ng
tati ticall y ignificant assoc iati on o f the 9 p2 1
SNPs with C AD? The 9p2 1 haplotype block i in
the middl e o f a tretch of DNA with no know n
fun ctio n. The cl o e t genes to the re po rted SNPs
are:
1)
MTAP
(meth ylthi oadeno in e
phosphoryla e), whi ch is in volved in polya mine
metaboli m and the alvage of ade nine and
methio nine; 2) CDKN2A and CDKN2B (cyc lin dependent kin a e inhibitor 2A and B ), whi ch are
tumour suppressor genes; 3) and DMRTA 1
(doublesex and mab-3 related tran c riptio n facto r
like famil y A 1), whi ch i important in ex ual
differe ntiati o n. However, these gene
are
approximately 45 ki lobase (kb ), 70 kb and 200
kb away fro m the stro ngest SNP
ignal
respecti vely. It is poss ible that vari ants at 9p2 1
co uld affect the e gene via regul atory ele ment ,
but this i diffic ult to determine usin g c urrent
techno logie . Moreover, it i diffi c ult to even
hypothes ize how the e gene c uld be in vo lved
in CAD ri sk. C learl y, there is much more to
learn and di scover.
In conclu sion, fo ur GW AS publi shed in
2007 that e nro ll ed large and non-o ve rl appin g
tud y popul ati o ns have identi fied a regio n o f
9p2 1 to be tro ng ly associated with C AD ri sk.
The effect ize is too small fo r the results to be
eas ily integrated into clini cal deci ion-mak ing
for a sin gle pati ent, but the tre ngth of the
associati o n suggests that there mu . t be a shared
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unde rl yin g biological mechanism, although the
actu al mechani sm remains unclear at this time.
Furthe r tudie to identify the reason for the
trong as ociation may lead to additional insights
into the progre sion , prevention, and treatment of
CAD.

References
I.

2.

3.

4.
5.

6.

7.

8.

9.

10.

I l.

12.

Lander ES , Linton LM , Birren B et a!. Initial
eq uenci ng and analysis of the human ge nome. Nature
200 I; 409: 860-92.
Venter J , Adams MD, Myers EW et al: The
seq uence of the human ge n me. Sc ience (New York,
y 2001 ; 29l: 1304- 135 1.
Frazer KA, Ballin ger DG. ox DR et al: A econd
generati n human hap lotype map o f over 3. 1 milli on
SNP . Nature 2007: 449: 85 1- 6 1.
Strac han T, Read, A: Human M lecul ar Genetic , 3rd
ed n: Garland Sc ie nce, 2003 .
Mayer B. Erdma nn J. chun kert H: Genetic and
heri tabi lity of coronary artery di ea e and myocardial
in farcti on. lin Re Cardi I 2007; 96: 1-7.
Helgadottir A, Thorleif on G, Mano le cu A et al: A
commo n variant on chromo orne 9p2 1 affect the ri sk
of myocardial in farct ion. c ience (New York, NY
2007 ; 3 16: 149 1- 1493 .
McPheron R, Pert em lid i A, Kavas lar N et al: A
commo n all ele on chromosome 9 associated with
coronary heart di ea e. Scie n e (New York, NY 2007 ;
3 16: 148 - 1491.
We lcome Trust a e Co ntro l ons rtium : Genomewide assoc iati on tudy o f 14,000 ca es of eve n
common di ease and 3,000 hared controls. Nature
2007:447 : 66 1-678.
ama ni NJ, Erdma nn J, Hall
et al: Ge nomewide
a oc iatio n analy i of cor nary artery di ea e. The
Ne England journal of med icine 2007; 357: 443-453.
Barrell J , Fry B. Maller J, Daly MJ : Hap! view:
analysis and visuali zati o n of LD and hapl otype maps.
Bi in ~ rma ti cs (Oxford, England ) 2005; 2 1: 263-265.
Teo KK, Ounpuu , Hawken et al: Tobacco u e and
risk of myocardi al in fa rcti o n in 52 countri e in the
INTERH E RT stud y: a case-control tud y. Lancet
2006: 3 8: 647-658.
Ge net J, Frohli ch J, odor G. McPher on R:
Recommendati on
fo r
the
manaaement
of
dys li pide rnia and the preve nti on of c:rdi ovasc ul ar
disease: summary o f the 2003 upd ate. CMAJ 2003;
169 :92 1-924.

Feature Article
Does being "South Asian" increase the risk of CAD?
Wajid Sayeed, Medicine 2010
Reviewed by Dr. Robert Hegele
Since ma ny di sea e aeti o logies have a ge ne ti c contributi o n, the u e of e thni c categori es (or "geographi ca l ancestries")
can be a useful way of integrating a ra nge of cultural and geneti c attributes in o rder to e luc idate the associatio n
between uc h factors and disease usceptibility. "So uth A ia" is u ua ll y defined a the area e nco mpas ing Pakistan,
Nepal , Bangladesh, India, and Sri Lanka. Numero us observatio na l tudi es have been done howi ng that So uth Asia n ,
both in itu in South Asia a nd in South Asian diaspora com muniti e , are at increa ed ri sk for cardi ovasc ular disease,
especially coronary artery di sea e (CAD ), a findin g with major impli cati ons for c linical practice in co untri es s uc h a.
Canada, where South Asian are the third most popul o u imrrugrant group . While not every South A ian may develop
CAD-related morbidity, o ne approach to preventive medic ine is the applicati o n of interventi o ns in a n e ntire at-ri k
population, rather tha n targeting interventi on to individuals o n a case-by-case ba is. S uch population-wide
interventions rru ght, however, do more harm than good if their ri sks and costs outwe igh the ir be ne fits, and if they
cau e the clinician or the pati e nt to neglect modifiabl e indepe nde nt ri k factors with a proven ca u ative ro le in disease
aeti ology. We therefore pre e nt a critical look at literature suggesting the use of South Asian ethnic ity as an
independe nt ri k factor in the development of CAD.

Epidemiology of CAD in South Asian
Populations
Unfortunately, there are no large multi-centre
studies performed in regions of South Asia, and
the national figure available from India are
based on pooling of studies taken from different
centres at different time points. More
importantly, such data are not directly
comparable with those from South Asian
diaspora communities, for which disease
prevalence estimates are so metimes more scarce
and less reliable than mortality rates. World
Heath Organization (WHO) data are typically
expressed as DAL Ys, but thi s is a flawed
measure of disease burden, and not nece sarily a
good indicator of ri k. Mortality from CAD in
India has been calculated to be 0.85 million in
men and 0.74 million in women, totaling 1.59
1
million deaths in 2000. For an Indian population
of 1.05 billion in 2000, this translates to a
mortality rate of 151 CAD death 1100000
people. Global mortality from ischaemic heart
disease,
which
correlate
closely
with
symptomatic
CAD,
stands
at
115
deaths/100,000? Like the DALY, mmtality is
highly ubject to local socioeconomic conditions,
and is therefore not a good indicator of risk.

Similar challenges exist in surveillance of South
Asian populations outside of South Asia, though
these are mitigated by smaller overall population
size. For instance, in Canada, ischaemic heart
disease mortality is roughly similar between
South Asian men and European-origin men:
approximately 320 deaths/100000 per year
between 1979 and- 1993,3 but is increased for
South Asian versus European-origin women: 145
versus 109.9 deaths per year between 1979 and
1993. The comparison is more valid than at the
international level, given more uniform soc ial
conditions
within
Canada.
Furthermore,
prevalence estimates within Canada between
ethnic group were made in the Study of Health
Assessment and Ri sk in Ethnic groups
(S HARE), which showed a prevalence of 8.6%
in the South Asian origin cohort compared to
4.9% in the European origin one. 4 Data in UK
and US cohorts show similar trend 5-6

Is risk genetic?
While the epidemiological data may support
increased cardiovascular disease ri sk in South
Asians versus other populations, this does not
necessarily imply that genetic factors in the
group described as "South Asians" are of
primary importance. Culture - includin o- diet
t>
'
activity and social factor - while "heritable," is
unlike the genome in th at the consequences of

uwo

77(?)?

cultural factor m determining ri sk mi ght be
more amenable to modification through
education and counseling. Some authors,
however, assert th at the degree to which risk is
increased among t South Asians is too high to be
7
acco unted fo r onl y by li fes tyle fac tor . Thi has
led to considerable di scu sion of whether or not
South Asian ori gin hould be considered an
8
independent ri sk factor fo r CVD di sease.
The attempt to find bi oc hemical marker
for genetically detem1ined risk i in its in fancy
and has met mixed res ults. Some wo rk has been
done
as oc1atm g
polymorphi sms
in
homocysteine metabolic pathways with carotid
atherosclero i ,9 but a cau ati ve link has not been
well-de cribed. Thus far, the only bi ochemi cal
marker with a clear as oc iation with South A ian
origin that i based in geneti cs, and not the
environment, i
a hi gh pla rn a level of
Lipopro tein (a), which has been con idered as an
emergi ng ri k fac tor by the U.S. Nati onal
Cholesterol Educati on Program (NCEP). 10 Both
.
d ata ] ?- strong l y
. . 111 and b as1.c sc1ence
c l mica
ugge t both that Lp(a) is under geneti c control
and th at ex pression of particular alleles plays a
causative role in atherosclerosis and the
aeti ology of thrombogeni c conditions.
Thi alone does not necessitate th at
elevated plas ma Lp(a), or any other independent
risk factor a sociated with South Asian origin , is
primarily to blame fo r the increased prevalence
and mortality of CAD in South A ians. The
importance of environment and life tyle over
geneti cs was hi ghli ghted in a stud y by Bhatn agar
et al in the Lancet, th at howed signi ficant
differences in cardiova c ular di sease ri sk fac tors
between siblings of So uth Asian ori gin who
lived in either West London or Punj ab state.
While so me risk factors, such as Lp(a), were
similar between the cohort , indi catin g a geneti c
component, blood glucose, beta cell function,
serum apo B, and body mass index (BMI) were
13
all appreciably worse in the UK coho rt.
Since
environment,
and
therefore
lifes tyle, obvi ously contributes to th e growth of
C AD amongst South A ians in Western
countri es, research is required to detennine
whether or not genetics, environment, or an
interacti on between the m fundamentall y ex pl ains
the increa ed ri sk. Un fo rtunately, to date no
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study claiming an increase in independent risk
factor amongst South Asians has properly
controlled for lifestyle factors - instead indirect
bi ochemical or anthropometric surrogates such
14
as insulin sensitivity, dyslipidemia,7 or central
15
adiposity have been u ed to argue that South
Asians are more susceptible to the effects of a
sedentary li fes tyle, perhaps by virtue of genetics.
Cultural attitudes towards diet and exercise are,
however, heritable or perhaps learned, and could
re ult in increased expo ure of South Asians to
negati ve life tyle fac tors, explaining the increase
in ri sk without the need to invoke genetics.
Culture can and does have a profound
impact upon how a group views health-related
lifes tyle choices, uch as frequenc y of exercise
or the content of the di et. On the question of
exercise, a small tudy (n = 56) published by Lip
16
and
coworkers
showed
South
A ians
presenting with ac ute MI were much less likely
than their Cauca ian counterparts to have
engaged in regular exerc i e. At lea t 12 other
studie on the general po pulation of South
A ian in the UK have been do ne. A systematic
review revealed that British South Asians were
generally le
ph ysicall y acti ve than their
"white" or "Eu ropean " co unterparts. 17
In the fi eld of di et and nutrition, the data
leave much to be de ired in terms of inter-ethnic
co mpari ons. Recent ev idence, however, shows
th at Canadi an South Asian on average con ume
a hi gher pro portion of calo rie as carbohydrate
than Euro peans, Abori ginal , or Chinese
18
per ons. In the arne cohort, consumption of
carbohydrate was in ver ely related to serum
HDL, a potent pro tecti ve facto r against CAD. In
prelimin ary data fro m sc hoo lchildren in the UK
'
South Asian ' tudents consumed les fresh fruit
and vegetable than white children did . 14 South
Asian cookin g, particularl y fro m northern India
and Paki tan does not typi cally in volve the use
of raw vegetables, and there i a strong reli ance
u~o n saturated fats for cooking, ev idenced by the
Widespread use of ghee (clarifi ed butter) and
khoya or mawa (precipitated who le milk) in
traditional food.

The validity of the concept of "Ethnicity"
The current literature does not recogni ze
potential genetic heterogeneity amongst South
Asians. Whil t thi s overall categori zation of
"South Asian" may be useful "shorthand" that
might simplify data collection, it is predi sposes
studies to sampling error: there might be
substrata in a ample labelled as being "South
Asian' that have different ri sk than others so
classified, but which would be falsely seen a
respresentative of the whole population.
India, Paki stan , Bangladesh, Nepal, and
Sri Lanka each have genetically and culturally
distinct ub-population , and cultural differences
need not track with genetics. Even in the
relatively confined space of Sri Lanka, 5
19
genetically distinct populations are discernible,
and Tamil and Sinhale e, the two large t
groups, both have the least in common , from a
genetic per pective, with India's Veddah s,
Gujaratis and Punjabis.20
Whether
genetic
or
cultural,
heterogeneity can be shown to manifest itself in
different cardiovascular ri sks between population
substrata. For in tance, Bangladeshi in the UK
have been shown to have the highest
cardiovascular risk of any South Asian group,
both from biochemical data, and from selfreported lifestyle factors, with Pakistanis also
21
having demonstrably higher risk than Indians.
These
national
groupings
("geopraphical
may
them selves
be
futher
ancestries")
misleading, given the significant cultural and
genetic overlap between North India and
Pakistan, as well as the over-representation of
certain ethnic groups within tho e countries in
the UK.
Given the history and ethnology of the
"South A ian" region, such use of generalized
ethnic origin as a risk factor cannot be justified
based upon the current evidence, which is as
imprecise as studies in "Europeans" that have not
differentiated
between
such
diverse
subpopulations as Italians, Finns Icelanders or
Ashkenazim.

Conclusions
Despite the volume of studies published, there is
no definitive evidence that South Asian origin
can be yet used as an independent risk factor

when considering a pati ent's CAD risk in order
to plan interventions. A with most indi vidu al
pati ent , bi ochemical an d bi o metric data may be
useful a "red flags " fo r the ph ysician, and more
precise indi cators o f ri k fo r the specific pati ent
since they mo re directl y reflect potenti al
underlying di sease proce es. C lini cians do no t
treat po pulati on , they treat indi vidu als, and each
ri sk profile i still related to
individu al'
behaviour, regardless of the geneti c contributi on.
Since genetic risk facto rs are not amenable to
modification, the sensible co urse of actio n is to
base treatment strategies upon the indi vidual
patient' hi story and circ umstances, and to make
the same key recommendati o n to South Asian
patients as i made to all other patients - the
adoption of a healthy diet and regular exercise.

References
1.

2.

3.

4.

5.

6.

7.

8.

9.

Gupta, R. Burde n of Coronary Heart Disea e in Indi a.
Indi an HeartJ. 2006 Jul ; l 24(1 ):15-22 .
Anonymo us. Cardiova c ul ar Di ease: Preventi o n a nd
Control [Internet]. World Health Orga ni zati o n. 2003
[cited
2008
01
25] .
A vail abl e
fro m
http://www . who. intldie tph ys ica lacti vity/publicati o ns/f
acts/cvd/e n/
She th T , Nair C , Nargundkar M , Ana nd S, Yu suf S .
mortality a mo ng
Cardi ovasc ular a nd cancern
Canadi a n o f Europea n, o uth A ian, a nd C hinese
ori gin fro m 1979 to 1993 : a n a nalys is o f 1. 2 milli o n
death . CMAJ.l 999 Jul ; 16 1: 132-8.
An a nd S, Yusuf S, Vuksan V, Devanese n S, Teo KK ,
Montag ue PA , Kele me n L, Yi C, Lonn E, Ge r tein H,
Hege le RA, McQuee n M , SHARE ln ve ti ga tors.
Differences in ri k fac tors. athero c le r si , and
cardi ovasc ul ar di sea e be twee n e thni c groups in
Canada: the Stud y o f Hea lth A es me nt and Ri k in
Ethni c groups (SHARE) . The Lancet. 2000 Jul ;
365 :279-84 .
Balaraj an R. Ethni c differe nce in mortality fro m
i chaern.i c heart di sease a nd cerebrova c ular di sea e in
Engla nd a nd Wales. BMJ. March 199 1; 302 :560 -4 .
Mc Keigue PM, Mille r GJ , Marmot MG . Coro nary
heart di sease in south A ia n overseas: review . J C lin
Epide mi o l. Jun e 1989; 42:597- 609.
Singh V, Deedwani a P . Dys lipi de mi a in Spec ia l
Popul ati ons: Asian Indi a n , A fri ca n Ame rica ns, a nd
Hi . pani cs. C urr. Athe rosc leros is Re p. 2006 ; 8 :32-40 .
Gupta M, Brister S. I So uth As ian e thnic it y a n
mdepe nde nt cardi ovas ul ar ri k factor? Ca n. J .
Cardiol. 2006 Aug; 22(3): 193- 197.
Kele me n LE, Ana nd SS , Hege1e RA , Sta mp fer MJ.
Ros ner B, Willet WC , Montague PA , Lo nn E, Vuksa n
V, Teo KK, De vanesen S, Yusuf S. Assoc iati ons o f
plasma
ho mocyste ine
and
the
meth yle netetrah ydro folate
reduc tase
C677T

77 ') ')

10.

11.

12.

13.

14.

15.

16 .

17.

18.

19.

20 .
2 1.

po lymorphj sm with carotid intima media thic kness
amo ng South Asian , Chinese a nd European
Canadian . Atherosclero is. 2004 Jul y; 176: 36 1-370.
Nati onal Cholesterol Education Progra m (NCEP)
Ex pe rt Pane l o n Detecti o n, Eva lua ti o n, and Treatme nt
of Hi g h Blood Cholesterol in Adults (Adult Treatme nt
Pane l ill) (2002) Third Re po rt of the Nati o nal
Chole te rol Education Progra m (NC EP) Ex pert Pane l
on De tecti o n, Evaluati o n, a nd Treatment of Hi g h
Bl ood C ho lesterol in Adult (Ad ult Treatme nt Panel
III) final re po rt. C irc ul ati o n. I 06: 3 143- 342 1.
Gazzaruso C, Buscag lia P, Garzaniti A, Falcone C ,
Mari otti S. Savi no S, Bo ne lli G , Finardi G , Geroldi D .
A ociati o n
of
lipoprotei n(a)
level
a nd
apolipopro te in(a) phenotype with coro nary heart
di ea e in patie nt with e e nti al hyperte nsion. J
Hyperte ns. 1997 M ar;15 (3):227-35.
Ko chin ky ML. Lipoprotein(a) a nd atherosclerosis:
new per pecti ve o n the mec hani sm of actio n of a n
e ni gmatic lipo pro te in . C urr A the roscler Rep. 2005
Sep; 7(5):389-95.
Bhatnagar D, Anand IS , Durring to n PN, Pate l OJ ,
W ander GS. M ackness MI , C reed F, T o me nso n B ,
Chandra he khar Y, Winterbo th a m M . Coronary ri s k
factor in peopl e from the Indian subco ntine nt li vi ng
in west Lo ndo n and the ir iblings in lndia. La ncet.
1995 Feb 18;345(8947):405-9.
Wrunc up PH , Gilg JA , Papacosta 0 , Seymour C ,
Miller GJ , Alberti KG , Cook DG . Earl y ev ide nce of
ethnic difference
in cardi ovasc ular ri sk: cross
ec ti o nal co mpari o n of British South Asian and white
c hildre n. BMJ. 2002 Mar 16;324(7338):635 .
Mc Keigue PM , Shah B, Marmo t MG . Re lati o n of
central bes ity and in ulin res istance with hi gh
di abetes prevalence a nd cardi ovasc ular ri sk in South
Asian s. La ncet. 199 1 Feb 16 ;337(8738):382-6.
Lip GY , Cader MZ, Lee F, Munir SM , Beevers DG .
Ethni c differences in pre-admi s io n leve ls of physical
admitted with myocardial
actJ VJty 1n pati e nt
infarcti o n. lnt. J . Cardio logy. 1996 June ; 56: 169- 175 .
Fi sc hbac her CM , Hunt S, Alexander L.How
physically acti ve are So uth Asia n in the United
Kin gdo m? A lite rature review. J Publi c Hea lth (Ox f) .
2004 Sep ; 26(3) :250-8.
Me rchant AT, Anand SS, Ke le me n LE, Yuk a n V,
Jacobs R, Davis B, Teo K, Yus uf S, S HA RE a nd
SHARE-AP investi gators. Carbo hydrate inta ke a nd
HDL in a multi e thnic po pul ati o n. Am J C lin Nutr.
2007 Jan;85( 1):225 -30.
Papiha SS, Mas tana SS , Jayasekara R. Genetic
variation in Sri Lanka. Hum Bi o i. 1996 Oct;
68(5):707 -37.
Kshatri ya GK. Genetic affiniti e o f Sri La nka n
po pul ati o ns. Hum Bi o i. 1995 Dec ;67(6):843-66.
Bhopal R, Unwin N, White M, Ya ll op J , Walke r L ,
Alberti KG , Harl a nd J, Pa te l S, Ahmad N, Turner C ,
Wa tso n B, Kaur D, Kulkarni A, La ke r M , T av rid o u A.
He te rogene ity o f coro nar y heart di sease ri sk factors in
Indi a n, Paki sta ni , B ang lade hi , and European o ri gin

UWOMJ 77(2) 2008 62

po pul a ti o n : cross sectio nal study. BMJ. 1999 Jul ;
3 19(7204 ):2 15-20 .

Feature Article
A Look at Cardiac Myxoma
Ahraaz Wyne, Medicine 2010
Reviewed by Dr. David Masse[
Cardiac M yxoma i the most common primary cardi ac tumor. It arises from the e nd ocardium as a lipidi c cell mas
e mbedded in a va c ul ar myxo id stro ma. M o t myxo mas are sporadi c and the cau e is large ly unknown. Fami li a l
variant with an autosoma l domi nant inheritance ex ist. Myxomas typically develop in female between the eco nd to
sixth decade of life . C linica l manife tati o n ca n mimic many cardi ac conditi o ns and depend o n the natura l behaviour
of the tumo r and its locati o n within the heart, ranging from co mpl ete ly a ymp LOmatic to causing udden death .
Establishing a n early di agno is is esse nti al and requires imag ing techniques. 2D-Ec hocardi ography is the diagnostic
modality o f c ho ice however, ultrafast CT or MRI may be required. The preferred treatment is urgica l re ectio n whi c h
is curati ve and should be performed as early a possib le to avo id yste mic co mpli cati o ns s uc h a embo li. Patient with
cardiac myxo ma ge nerall y have an exce ll ent prog nos is. Following surg ical re ecti o n, scree nin g for rec urre nce is
prudent, especia ll y a mo ng th e famili a l varia nts, where the rec urre nce rates may be as hi gh a 20%. Myxomas,
although rare, pre ent a vari ed c lini ca l picture and represe nt a diagnostic c ha ll e nge. Co n eq ue ntl y, physicians must
have a high index of su pic io n, since pro mpt surgical removal improves quality of life and ex tends survival.

Introduction
The fir t de cription of a left atrial myxoma is
1
accredited to King in 1845. A recent review of
Carl Rokitansky' collection has revealed a 170year old perfectly con erved myxoma of the
pulmonary valve; the patient died in 1833?
Prior to 1951 the diagnosis was made primarily
at postmortem examinations; in that year, an
intracavitary left atrial tumor was diagnosed by
angiography.3 The first succe sful excision of a
4
left atrial myxoma was performed in 1955.
Primary tumors of the heart are rare clinical
entities and studie estimate the incidence as
being between 0.0017% and 0.19% at autopsy,
among unselected patients. 5 Cardiac myxomas
are the most common of the primary cardiac
tumors
comprising
about
30-50%.
Approximately 75 % are located in the left atrial
cavity, 23% in the right atrial cavity, and about
46
2% in a ventricular cavity. • While extremely
6
rare, tumors may be found in multiple cavities.
Cardiac
myxomas
have
varied
clinical
presentations which primarily depend on the
cardiac chamber where they occur and thu
present a challenge for early diagnosi s.
Epidemiology and Clinical Practice
Epidemiology: Myxomas occur in all age group
but are particularly frequent between the third
and sixth decades of life. The youngest known

patient was a stillborn infant, and the oldest a 95year-old woman .4 The majority of myxoma are
sporadic and tend to be single, atrial , and more
typically in women. 1 Approximately 10% are
familial ,
with
an
autosomal
domin ant
7
inheritance. At pre ent, the Carney complex is
used to describe an autosomal dominant trait that
include cardiac myxomas, cutaneous myxomas,
spotty
pigmentation s
on
the
skin,
endocrinopathy, and both endoctine and nonendocrine
tumors. 8
These
patient
are
considerably younger at the time of diagnosis
when compared to patient with sporadic
myxomas.4
Pathology: Histological examination
how
atrial myxomas arising from the endocardium ,
commonl y attached at the border of the fossa
ovalis in the left atrium. 4 The cells ari e from
multipotential mesenchymal cells and are
characterized as lipidic cell embedded in a
4
vascular myxoid stroma. Tumors vary in shape
from round-oval to polygonal , and often show
calcification, necrosis and/or hemorrhage (see
9
Figure 1). The expres ion of interleuk.in-6 (IL6) by atrial myxomas has been widely reported
in the literature and is believed to aid tumor-cell
proliferation and differentiation.'' In one series
of 37 cases of myxoma, 74% howed expre sion
5
of IL-6. The malignant potential of cardiac
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Figure 1. Histo log ic section show ing polygonal lipidic
cell s embedded in an ac id-rnucopo ly acc hari de va cul ar
. 4
rna tnx.

myxo ma remains doubtful, although there have
been reports of remote myxo matous growth that
has emboli zed. 18
Clinical Presentation: While small myxo mas
can be asymptomatic, the maj ority present with
one or more of the tri ad of intracardiac
o bstructi on, cardioemboli sm, and/or nonspecific
constituti onal manifes tations; The clini cal
presentation will vary depending upon the
ph ysical behaviour of the tumor and its locati on
within the heart.
A. Physical Behaviour: Obstructi on of the
circulati on th ro ugh the heart or heart valves
commonly gives ri se to ymptom of left(dys pn ea,
recurrent
pulmonary
ede ma,
paroxys mal nocturnal dyspnea, orthopnea) or
right-sided (peripheral edema, asc ite , fati gue,
hepatomegaly) heart-failure, often mimicking
mitral or tri cuspid stenosis. The severity of
sympto m will depend upon th e ex tent of
o bstruction and can vary with body po iti on. If
the tumor is large, eas ily defonnable and has a
long stalk, then temporary co mplete obstructi on
of the mitral or tricuspid valve ori fice can occ ur,
res ulting in syncope, di zziness (20 % o f pati ent. )
4
or sudden death . Interference of the tumor with
heart valve fun cti on may produce symptoms of
valvular in uffi ciency. Thi s occ urs du e to
movement of the mass back and forth between
the atrium and ventricle (" wrecking ball" effect),
hamperin g proper valve clos ure or damagin g the
4
A V-valve apparatus (e.g. chordal rupture).
In vasion o f the myocardium can cause impaired
contractility, supraventri c ular arrh ythmi as, heart
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block or pericardia! effu sion. If the myxoma
in vades adj acent lung tissue, pulmonary
symptom
can manifest, often mimicking
bronchogenic carcinoma.
Emboli zati on, which occurs in 30-40% of
4
myxo mas, is usually syste mic but may also be
pulmonary; it will depend on the tumor's
chamber of origin . It is for this reason th at
myxo ma should always be on the differential for
pulmonary embolism, pulmonary hypertension ,
and embolic stroke .
Constituti onal or ystemic symptom such as
fa ti gue, fever, ras hes, joint pains and weight loss
can also be seen. Laboratory abnonn alities are
usually seen as elevated inflammatory markers
(erythrocyte sedimentati on rate, serum C -reacti ve
pro teins and globulin levels) as well as anemi a,
4 11
and
hi gh serum
interleukin-6
levels. ·
So metime , low grade but long-standing fever
can be the onl y ymptom.9
B. Location: The maj ority (75 %) of atrial
myxomas arise in the left atrium and up to 23 %
percent in the ri ght atrium. Mo t arise from the
inter-atri al septum at the border of the fos a
ovalis, but they can al o originate, in de cending
order of frequency, fro m the po terior atri al wall,
the anteri or atrial wall , and the atri al
appendage. ' .4 Tumors can also grow into the
atri al lumen and cause ymptoms of blood flo w
ob tructi on or create mitral in sufficiency, which
are symptoms often assoc iated with commoner
condition
uch a mitral valve di ease, heart
failure
and/or
econdary
pulmonary
hypertension. If the tumor moves within the
atrium, depending on the length of its talk and
ex tent of attachment to the eptum, symptomatic
alterati on can occur with changes in body
pos iti o n. M yxo mas can also e mbolize producing
serious pulmonary and neuro logic equelae.
Ph~sical Examination: Phy ical signs are highly
van able and depend upon the clinical
pre entati on and the ori ginating chamber of the
myxo ma. For example, right atrial myxomas
may manifest as elevated jugular venou
pressure or a pro minent a wave. If the myxoma
leads to v al~ular damage ( tenosi /regurgitation),
then ys to hc or di as tolic murmurs may be
au cultated. A loud S 1 will be heard if there i a
delay in mitral valve closure due to tumor
prolapse into the valve ori fice (mimicking mitral

stenosi ). The intensity of P2 may also be normal
or increased, depending upon the presence of
pulmonary hypertension. 4 In many ca es, an
early dia tolic so und called a 'tumor plop' i
heard, as the tumor impacts against the
endocardial wall m left and right sided
8 10
myxoma . "
Upon
general
examination,
ystemic signs could include fever, cyanosis,
clubbing, rash , or petechiae. Patients with
familial or syndromic forms of myxoma may
also have feature including skin pigmentations
or endocrine abnormalities such as Cushing's
Syndrome. 8

Diagnosis
The goals of diagno is are three-fold: to ascertain
whether a tumor exists, determine its location,
and to characterize it. Diagnosis of myxoma
require a high index of suspicion and, because
of the non-specific nature of laboratory testing,
require various imaging studies.'+
Echocardiography first successfully showed a
4
left atrial myxoma in 1959. Today, because of
its wide availability and simplicity, 2Dechocardiography is an excellent noninvasive
tool for initial evaluation. It typically show
unimpeded images of the atria, septae and
ventricles making it helpful in detecting tumor
location (see Figure 2) and morphology (cysts,
calcifications, necrotic foci, and hemorrhage). 4
Doppler techniques aid in determining degree of
cardiac obstruction or valvular damage. In many
situations a tran esophageal echocardiogram
(TEE) is preferred as it provides superior images

Figure 2. One-dimensional echocardiogram
4
apical view of a biatrial myxoma.

showing characteristics of the tumor and location
in relation to the interatrial eptum.
Sometimes, newer imaging techniques
such a cardiac MRI and ultrafast-CT may be
required ; both provide noninvasive, high
reso lution cross-sectional v1ews of cardiac
structures. Cardiac MRI is generally preferred
becau e of its hi gher resolution (Figure 3) and
ability to reflect chemical microenvironments
within a tumor by differential Tl- and T2weighting; however tumors must measure at
4 J? 13
lea t 0.5 em before they are detectable. · -· CT
scanning is u eful when MRI is unavailab le or
contraindicated. Finally, contrast angiography
ha al o been u ed in the diagnosis of myxoma
however catheterization is more invasive and
run the risk of embolizing tumor fragments. A
study by Agostini et al. howed that positron
emi ion tomography (PET) could also be used
13
in the diagnosis of myxoma, however PET
remains widely unavailable in Canada and may
not offer reso lutions comparable to MRI or CT.

Treatment
The treatment of choice for myxoma is curative
4
surgical resection . After a review of the
literature, there appears to be no known medical
therapy for shrinking or preventing recurrence of
myxoma and drugs are primarily used to manage
symptoms, such as heart failure, or when trying
to differentiate tumor from thrombu s (e.g.
anticoagulants).
Furthermore, there are no
recommended dietary modifications and life tyle
activities are permitted as tolerated.
Once a presumptive diagnosis ha been made,
most surgeon recommend prompt resection to
avoid embolic complications uch as sudden
14 15
death. " Thi s include asymptomatic patients

Figure 3. A cardiac MRI showin g left atri al myxoma in
the Transverse (left) and saggital (ri ght) plane .4
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who have had incidental findings of myxoma
during routine echocardiography. Surgery entails
performing a median ternotomy and ubsequent
tumor excision with the use of mild general and
deep topical hypothermia, cardioplegic cardiac
arrest, and cardiopulmonary bypass .~ Care is
taken to avoid intraoperative fragmentation a all
chambers of the heart are in spected for
multifocal disea e. If there is associated valvular
damage, then thi s is corrected with annulopla ty,
16 17
repair or replacement. · The results of surgical
re ection are generally very good with most
series reporting operative mortality rates under 5
14 17
percent. - M ajor complications of the surgery
include tumor embo lization, supraventric ular
arrhythmias and requirement of permanent
4
cardiac pacing due to conduction di turbances.
Alternative
surgical
approaches
using
endoscopic tumor re ection have also been used
for their co metic advantage and faster recovery.
Recurrence is low, close to 5% in pati ents with
sporadic myxomas but can be a high as 20%
7
with the familial variant . As such , there is a
need for careful follow-up and biannual 2-D
echocardiograms would be reasonable. In rare
ca e
of
freq uent
recurrence ,
cardiac
17
tran plantation has also been performed.

Conclusion
Although rare, myxoma IS the mo t common
type of primary cardiac tumor and requires a
high index of uspicion. For the patient' illness
experience,
myxoma ran ges from
being
completely asymptomat ic to causin g severe
morbidity and sudden death , with symptom s
suggestive of many card iac causes. Surgical
removal offers curative treatment with excellent
prognosis and recurrences are rare. Thi s paper
has briefly provided an overv iew of cardiac
myxom as as probably pre enting the most varied
clinical picture of all card iac tumors.
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